Inventiva - ADR Aktie

Thank you. Good day and thank you for standing by. Welcome to Inventiva's First Half of 2026 Financial Results Conference Call. At this time all participants are in listen only mode. After the speaker's presentation there will be a question and answer session. As a reminder, today's conference call is being recorded. I would now like to hand the call over to David Nicodem, Head of Investor Relations for Inventiva. Please go ahead.

Thank you. Good morning. Good afternoon. Thank you for joining Inventiva's first half 2026 financial results and business update. This morning we issued our press release reporting our full financial results for the first half of 2026. A replay of this webcast will be available in the investor section of our website following the call. Before we begin, a quick reminder that the statements we make today, including during the Q&A, may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect our views only as of today and should not be relied upon at any later date. Please refer to slide 2 and to our filings with the SEC and the AMF for discussion of the associated risks.

Joining me today are Andrew Obenshain, our Chief Executive Officer, Dr. Jason Campagna, our Chief Medical Officer and President of R&D, and Axel-Sven Malkomes, our Chief Financial Officer. Chris Benecki, our recently appointed Chief Operating Officer, will be joining us for the Q&A portion of the call. With that, I'll turn the call over to Andrew.

Thank you, David, and welcome everyone. Today I'll start by providing an update on the company and our priorities. Jason will overview our Lanifibranor Development Program. Axel will walk through our first half of 2026 financial highlights, and then we will open the call for Q&A. The first half of 2026 has been a defining period for Inventiva. We have stayed focused on our near-term objectives, advancing Lanifibranor toward the Phase 3 top line results readout in MASH expected in Q4 2026, preparing for regulatory filing while building your organization to support a potential commercial launch. Let me start with why we believe in the potential of Lanifibranor and why a potential new therapy for MASH is so important.

It comes down to 3 key elements, differentiation, late stage validation, and market opportunity. Let's begin with differentiation. MASH is driven by both intrahepatic and extrahepatic processes, and Lanifibranor is designed to address both through a single, once-daily oral therapy. In our NATIVE Phase 2b study, Lanifibranor showed improvement across all key histological endpoints. Next is validation. We designed the NATIVE 3 Phase 3 trial to build on the foundation established in our positive Phase 2b study. We look forward to reporting top-line data in the fourth quarter of this year. And finally, market opportunity. The market is being built in front of us. If Lanifibranor is approved, we will enter an established therapeutic area with a market potential expected to exceed $15 billion by 2035.

However, significant unmet need remains, and this represents a meaningful opportunity for Inventiva to bring a potentially differentiated treatment option with Lanifibranor to people diagnosed with MASH, if approved. Let me take each in turn and then lay out our priorities for the year ahead. Let's start with differentiation, and it begins with understanding the biology of the disease. MASH is not simply a liver problem. It is the hepatic expression of a broader systemic metabolic dysfunction. As slide 6 shows, the disease is driven by multiple interconnected pathways, both outside and inside the liver. These include insulin resistance, adipose dysfunction, and dyslipidemia on the extrahepatic side, and steatosis, inflammation, and fibrosis within the liver itself.

That has clear implications for treatment. If the disease is driven by several processes at once, there is an opportunity for next-generation treatment to target more than just 1 driver. That is the unmet need we believe Lanifibranor could address if approved. Our aim is not only to target the liver, it is to modulate pathways across both the metabolic and hepatic components of the disease and bring a differentiated treatment option to patients with MASH. The differentiating mechanism of Lanifibranor modulating both pathways is reflected in compelling clinical data. In our Phase 2b study, after 6 months, Lanifibranor delivered an 18% placebo-adjusted improvement in fibrosis, 26% on MASH resolution, and 24% on the composite endpoint. Those results are the foundation for NATIVE 3.

We are now testing the same approach in a larger controlled Phase 3 population of patients with F2 and F3. That is what makes NATIVE 3 so impactful. It was designed to confirm at pivotal scale the biology and activity we observed in our Phase 2b study. And we are pursuing this in a market with substantial and growing unmet need. As slide 8 shows, there are an estimated 18 million Americans living with MASH, yet only 10% are diagnosed. That is changing fast. As the treatment landscape has matured, diagnosis has increased, up roughly 25% versus 2024. And that is translating into a larger population being actively identified and managed.

Today, approximately 374,000 patients with F2 or F3 disease are already in treatment or under the care of a physician. The picture is clear. A large, prevalent patient population expanding rapidly as awareness and testing improve, and it could a compelling opportunity for Lanifibranor if approved. Turning to slide 9, to see where Lanifibranor may fit in the treatment paradigm, it helps to think about MASH in terms of 2 factors that are top of mind for physicians. Severity of fibrosis, and the cardiometabolic factors that can influence the risk of disease progression. Put fibrosis on 1 axis and cardiometabolic risk on the other, and 4 clinically distinct populations come into view. Start with the lower right quadrant. We have patients with F3 MASH and cardiometabolic risk, such as type 2 diabetes. This is a population with high unmet medical need.

With the mechanism of action of Lanifibranor could be compelling in that it targets both the liver and the metabolic driver simultaneously. In our Phase 2b trial, Lanifibranor demonstrated an 18% placebo-adjusted improvement in fibrosis at just 6 months. Similarly, in the lower left, although these patients have earlier stage F2 fibrosis, their cardiometabolic risk factors can put them at risk for more rapid disease progression. For these patients, physicians may also want to act urgently and Lanifibranor for potentially offer an opportunity to intervene earlier in the course of the disease if approved. Moving to the top right quadrant. By extension, Lanifibranor could be well positioned in patients who have F3 fibrosis without significant cardiometabolic risk. Here, the fibrosis itself is the primary concern, and Lanifibranor may have the potential to address the underlying liver disease before it progresses.

Taken together, these 3 quadrants represent a large population with significant unmet need. And if approved, we believe Lanifibranor has the potential to play an important role in addressing the needs of these patients. With that overview of why we believe in the potential of Lanifibranor, let me lay out 3 key priorities we are focused on to unlock new opportunities for patients with MASH. First, the NATIVE 3 trial. We remain on track to report top-line data in the fourth quarter of 2026. Earlier this month, the last patient completed their final, second-to-final, and final 72-week visit. The main cohort enrolled 1,009 participants, all with biopsy-confirmed non-cirrhotic MASH and F2 or F3 fibrosis. Second, regulatory readiness. We are advancing our preparations now to support a potential NDA submission with the FDA in the first half of 2027, positioning us to move quickly into regulatory interactions if the top line data readout is positive.

And third, commercial readiness. We are building a commercial organization with the depth and breadth of experience with the best disease products to be ready for the potential launch in 2028. We believe we are moving forward with Lanifibranor from a position of strength and with the potential for a differentiated profile, a late-stage validation opportunity with NATIVE 3, and a significant market opportunity if approved. I'm truly energized by the potential to make a real difference for millions of people living with this serious disease. With that, let me hand it over to Jason to take you through the science behind Lanifibranor and our clinical program.

Thank you, Andrew, and greetings, everyone. I'll spend a few minutes on 4 aspects of our Lanifibranor development program in MASH. 1, how Lanifibranor is designed to address the spectrum of disease. 2, what we've observed in the positive NATIVE Phase 2b clinical trial. Third, how our NATIVE 3, Phase 3 trial is built to confirm that Phase 2 study. And lastly, where we're thinking of taking the program next. Let me start with the molecule. Slide 11 shows Lanifibranor as a potential novel new chemical entity, structurally and mechanistically distinct from both fibrates and thiazolidinediones, and recognized by the FDA with both Breakthrough Therapy and Fast-Track designations.

It was informed by decades of research on PPAR biology and the development learnings of prior compounds. And it rests on 1 critical concept, balance. Lanifibranor engages all 3 PPAR isoforms, alpha, delta, and gamma, in a low-potency, balanced manner such that no single receptor biology dominates. It was also engineered to have only partial agonism of the PPAR gamma receptor. The combination of this balanced low-potency pharmacology and partial PPAR gamma agonism are the keys to our differentiation. This is what lets Lanifibranor modulate in harmony the metabolic, inflammatory, and antifibrotic pathways of MASH combined rather than forcing 1 mechanism or receptor at the expense of the others. The 2 charts on the right illustrate this design pharmacology. On the first panel, we see the balanced activation profile and the approximately 80% gamma activation with Lanifibranor, while on the far right, the cofactor recruitment fingerprint that sets Lanifibranor apart from full TZD gamma agonists. Result is a once-daily oral therapy intended to deliver a physiologic balance between achieving PAN-PPAR activation and avoiding any 1 receptor dominance.

Moving now to our Phase 2b NATIVE Clinical Trial Data. Andrew shared our overall histology efficacy data, but that included patients with lower risk earlier F1 disease. When we exclude these patients with earlier stage disease, we continue to see robust effects across all 3 histologic endpoints, showing that the drug worked equally well in both early and later stage disease. And these results were achieved after only 6 months of treatment. Looking more closely at the data for the composite endpoint, you can see that treated patients were roughly 8 times more likely than placebo patients to achieve dual histologic improvement in the type 2 diabetes subgroup. Thank you. This tells us that spontaneous regression of the disease was uncommon and that the treatment effect of Lanifibranor was strong. Together with the early and late stage data, these results underscore the potential of Lanifibranor to perform across the disease spectrum, including in patients with the most urgent disease.

Let me now turn to safety and tolerability. On slide 13, we show the most frequently reported adverse events by investigators in our NATIVE Phase 2b clinical trial. Lanifibranor was generally well tolerated across the totality of our Phase 2 program, but the adverse event profile in NATIVE 2b tracked closely with the underlying scientific design of Lanifibranor. Consistent with our preclinical toxicology data, we saw minimal classic alpha or delta toxicities. Gamma-related effects, weight gain, edema, and hemoglobin decline, these were present but attenuated relative to the full TZD class gamma agonists. The weight gain we observed in patients treated with Lanifibranor is biphasic. Early on, the partial PPAR gamma activation acts on a sodium channel in the kidney, resulting in sodium and water retention.

While in a later phase, that same partial PPAR gamma activation drives improved insulin sensitization and adipose remodeling, reflected in the rise in adiponectin, tied to histologic efficacy. Both phases are consistent with the known pharmacology of PPAR gamma engagement, and based on our legend study, these gamma-related effects were mitigated by adding an SGLT2 inhibitor, empagliflozin, while also preserving the metabolic benefit of Lanifibranor. This brings me to NATIVE 3. This is a Phase 3 global registrational trial, and it was deliberately designed to build on our Phase 2b, the same 2 doses, a similar patient population, and a primary composite endpoint of MASH resolution and at least 1 stage fibrosis improvement in the same patient. Secondary endpoints include MASH resolution and fibrosis improvement of 1 stage or more. The trial enrolled approximately 1,400 patients across 2 cohorts, a placebo-controlled randomized portion consisting of 1,009 patients with biopsy-confirmed F2 or F3 MASH. And an exploratory cohort of 410 patients with predominantly F1 or F4 disease. Both cohorts were treated for 72 weeks.

All patients who completed the trial are eligible for an active treatment extension to support a longer-term view of the safety and tolerability of Lanifibranor. The main cohort will serve as the basis for global marketing registration, and the primary endpoint is powered at 90% on deliberately conservative assumptions with a higher placebo response and a lower treatment effect than we observed in the Phase 2b NATIVE trial. It is stratified by fibrosis stage and diabetes status. This main cohort also reflects the real world. The NATIVE 3 population is a contemporary MASH population, with higher diabetes prevalence, more advanced fibrosis, and more use of GLP-1s and SGLT2 inhibitors compared to our Phase 2b trial. As Andrew noted, it has been fully recruited, and the last patient visit for the week 72 portion of the trial was completed earlier this month. And as Andrew shared, we are excited for top-line data in the fourth quarter of this year.

Subject to positive Phase 3 results, we intend to file for accelerated approval with the FDA and conditional approval with the EMA. We will also be initiating a confirmatory clinical outcomes trial designed to evaluate the effects of Lanifibranor in patients with more advanced disease. That's worth pausing on because everything I've described targets the core pathophysiology of MASH. That same pathophysiology also underlies Compensated Advanced Chronic Liver Disease, or CACLD, due to MASH. These are patients who have progressed to advanced fibrosis or early histologic cirrhosis, yet they remain clinically compensated but have evidence of clinically significant portal hypertension. The primary driver of adverse liver-related outcomes. This subgroup of patients has no approved disease-modifying therapy. It is a significant area of high unmet need in the disease. We believe that Lanifibranor is mechanistically compelling in CACLD because the same PPAR isoforms that drive the histologic and metabolic effect in the non-cirrhotic MASH population also act on the vascular biology that underpins portal hypertension in this more advanced group. And in CACLD, portal pressure matters because as the disease advances, portal hypertension and not fibrosis alone becomes a key driver of these hard clinical outcomes, including bleeding, ascites, and liver transplant.

We recently published an analysis of our Phase 2b NATIVE trial showing a correlation in patient biopsies with vascular remodeling we've observed preclinically. Exploratory analysis, but they add to our conviction to pursue further advanced disease states in MASH. With that, I'll hand it over to Axel.

And I will pick up for Axel here.

Yes, I'm sorry. I lost my text. Please go ahead. Yep so good, I.

So this morning we issued our press release reporting our full financial results for the first half of 2026. Axel will focus on the key financial highlights and our financial position as we approach the NATIVE 3 top line readout. Axel, are you ready to take over? Not yet. Okay. As of June 30, 2026, we had €233.9 million of combined cash, cash equivalents, and short-term deposits. And we significantly strengthened our financial position through the comprehensive capital structure optimization that we announced in June. Under that, we bought back approximately 60% of the EIB warrants with anti-dilution protection for €50 million, and repaid our EIB loans for €63 million. In addition, the remaining EIB warrants with anti-dilution protection were cancelled and then Inventiva issued new EIB warrants in exchange described in the July 9, 2021.

I'm ready to take over. Please go ahead. As part of this optimization, we secured new debt financing of up to €130 million in 3 committed tranches, subject to conditions, with an initial drawdown of 2 tranches of €75 million gross, plus an additional uncommitted tranche of up to €20 million, as described in our press release of June 2, issued earlier this year. We also completed an underwritten public offering of our American Depository Shares, generating gross proceeds of €103 million. Together, these actions strengthened our balance sheet, extended the maturity of our debt, and simplified our capital structure. Our current financing assumptions, existing resources, and completed financing transactions provide cash runway until the end of the second quarter of 2027. Seeing us through key milestones, the Phase 3 top line data readout and potential NDA filing. Assuming full exercise of tranche 3 warrants on the back of a positive top line result, as well as successful completion of tranche C of the debt financing transaction, cash runway would extend to the start of the first quarter of 2028. R&D expenses were €46.2 million in the first half of 2026, brought in line with the prior year and reflecting continued clinical development of Lanifibranor and MASH. Marketing and business development expenses increased to €2.6 million and G&A expenses increased to €22.2 million. Overall, we entered the second half of 2026 with a strengthened balance sheet and financial visibility for the company.

With that, I'll turn the floor back to Andrew for his closing remarks.

Thank you, Axel. This is truly an exciting time for Inventiva. Our differentiated mechanisms of action, the results we saw in the NATIVE Phase 2b trial, and the robust design of our NATIVE Phase 3 trial provide a strong foundation as we approach the milestones ahead. The next major milestone is our NATIVE 3 Topline Results Readout expected in the fourth quarter of this year. Positive it could support a U.S. regulatory filing in the first half of 2027 and a potential EU filing to follow. And if approved, we're prepared for a potential U.S. commercial launch in 2028 with the goal of bringing a new treatment option to patients with significant unmet need. We also expect to initiate an outcomes trial, which could support a potential opportunity for Lanifibranor to expand into more advanced disease populations. Stepping back, what does this all mean for Lanifibranor? Let me bring it back to where I started. Why Lanifibranor and why now? Lanifibranor was designed to target both the metabolic and hepatic drivers of MASH in 1 oral medicine.

NATIVE 3 top line results readout is imminent in Q4 this year. The market is established and significant unmet need remains. We have established the foundation to build a launch-ready organization and prepare for the next stage of development, moving forward from a position of strength with the discipline and the urgency that people living with MASH deserve, and I'm genuinely excited about what lies ahead. With that, let me hand it back to the operator to begin Q&A. Operator?

Thank you. We will now open lines for questions. [Operator Instructions] We'll now move to our first question. And our first question comes from the line of Yasmeen Rahimi from Piper Sandler. Please go ahead.

Good morning, team. Congrats on all the updates, and thank you so much for walking us through some of the key questions. Maybe we've been lately getting questions from investors how we should be thinking about the 2 doses in the NATIVE study, and the NATIVE 3 study, and whether it would even make sense commercially if both showed a clinically meaningful difference to move forward. Would love to get your thoughts, and maybe 1 other 1 that sometimes comes up is that the higher dose had a phenomenal histological benefit, but then when we compared the NITs, the 2 doses looked more the same. So would love if you could maybe comment on both. That would be very helpful, as it's on top of you of the investors that have been asking us that. Thank you.

Thank you, Yasmeen, and good morning. So 2 questions in there. First 1, I think more of a commercial question, which I'll take, and then I'll pass it on for the correlation with histology and those to Jason in a second. If both doses are positive, are statistically significant positive, I think it would make sense to bring both forward in the market. It's going to depend on the data. So we'll clearly look at what the efficacy is with each dose and the tolerability of each dose. And if there is a there were to be scenarios in which the difference between the 2 makes sense to bring both the market potentially 1 for 2 patients or 1 you could think of as earlier stage patients that are less urgent and so therefore would be okay with a dose response of lower efficacy and more more tolerable, and if another 1, if you have, if there's a tolerability difference between low and high, then a higher dose with still tolerable, but a slightly different profile, you could see bringing both forward.

But that's really remains to see in the data. It's a little bit too early to speculate until we get the actual data to see it. Jason, let me hand the second question over to you, the correlation of NITs.

Sure, happy to Yasmeen, good morning. So in the NATIVE Phase 2 trial, generally speaking, the histology endpoints tracked well with most, but not all, of the clinical biomarker endpoints. Obviously, ALT-AST reduction was evidence. This reflects a hepatocellular injury, but moving into fibrosis, you can see that the Think of the data that we had as looking at both new scar being laid down and active scar resorption. PRO-C3 is the best example of new scar being laid down. It's a fragment of the collagen peptide, and the PRO-C3 marker actually tracked quite nicely with the 1,200 milligram histology efficacy endpoint. Similarly, when we look at ELF, the hyaluronic acid was a little noisy at baseline, but the 2 other components actually tracked very nicely in a dose-dependent manner, representing that we were, in this case, laying down, resorbing some existing scar. And lastly, on the TE, the range, you know, it's very difficult to compare trials, Yasmeen, as you know, across different sponsors, but when you look at the data ranging from 6 months to 18 months, the range in TE, liver stiffness measurement, ranges from about a 1% placebo-adjusted change all the way up to like a high, uh, sorry 1 kPa up to a high of 3 kPa.

So that's somewhere around 10% to 30%. Lanifibranor came in at the lower end of that range, and it's our belief that do that's 1. It's just early in the disease to really have movement on liver stiffness, the composite view of what's going on in the liver. And more importantly, we know that Lanifibranor has some confounding due to that fluid retention. This is a known concern with liver stiffness in general, listed in the the ECHO SENS manuals about being cautious about getting liver stiffness data after a meal or in the presence of fluid loading, and at 6 months, the dynamic fluid flux that's still happening due to the PPAR gamma, we believe is likely impacting some of that. So we landed at about a 10% reduction in liver stiffness, about a 1 kPa placebo, which just a number, and we're confident that with a longer treatment duration, the underlying fibrosis improvements will, in the end, dominate that signal by 18 months.

Thank you so much. Thank you. We'll move on to our next question. Our next question comes from the line of Rami Katkhuda from Fisai Capital. Please go ahead. The line is open.

Hi, guys. Thanks for taking my questions as well. Maybe going off a comment Jason made earlier, can you touch on the time course of Lanifibranor-associated weight gain, particularly the timing of early fluid retention versus later adipose remodeling and when each typically plateaus? And then secondly, I know it's a bit early, but how are you thinking about design of the confirmatory outcomes trial, and are there any key learnings from ongoing studies that could help inform patient selection?

Yes, thanks, Rami. So, 2 questions there just on the time course, which I'm just a preemptive. We can't really say much more than we've already said on this call. I think we've answered that question pretty thoroughly. So, maybe we could focus, Jason, on the F4 and the confirmatory study and what we're thinking there.

Yes, I'm happy to. I think, look, we're looking forward to talking more the confirmatory study after top line, but I think for now, what we're trying to communicate is 1 that will be focused on this decompensated chronic advanced compensated liver disease population, those with clinically significant portal hypertension. We know now that there are very, very good ways to assess and identify these patients in the wild using non-invasive methodologies like a combination of liver stiffness measurements and platelets. They're captured in criteria that providers use routinely in the care of patients with advanced liver disease. So the inclusion of patients with clinically significant portal hypertension, attention is the goal. Second, you ask what what evidence might we have from our clinical program that will inform that trial? Good question. The exploratory cohort I mentioned during the scripted portion of the call, we have approximately 75 to 100 cirrhotic patients in that trial that will have been exposed to Lanifibranor for at least and if they complete the active treatment extension, they could be on for up to 4 years. We think that those data from a safety and tolerability perspective and pharmacology will be helpful.

And lastly, we have completed nearly a quarter a dozen Phase 1 clinical trials with Lanifibranor over the years, including dedicated hepatic impairment study in patients with Child-Pugh A, B and C. And the results of those studies, although we haven't published them, we are comfortable and confident around the safety of the drug in those Phase 1 trials at the doses. We're presently using. And when combined with that exploratory cohort of about 75 to 100 patients, we think we'll have a really good opportunity to build and conduct a strong outcomes trial in this CACLD population.

Awesome. Thank you, guys. Thank you. We'll move on to our next question. And our next question comes from the line of Sylvie for Sushila Hernandez from Van Lanschot Kempen. Please go ahead, your line is open.

Hi, this is Sylvie on for Sushila. Thank you so much for taking your questions. So with the Lanifibranor Phase 3 NATIVE top line readout in MASH expected in the next quarter, we were wondering what kind of data we can expect at the top line. So will there be data on the treatment response in patients on GLP-1 and on SGLT2? GLP inhibitor or on the weight gain. And then if I could just ask another question, we were also wondering, how do you expect the placebo response to evolve with the longer treatment duration? Thank you.

So, Sylvie, thank you for the question. We are not guiding on the top line data right now. I think we, as you can tell on this call, we are very well aware of the interest and with 10 points and a tolerability profile elements I'm sure people are interested in seeing and I'm sure we will be looking to address a lot of the questions that were on the call today, however we're not yet guiding on what's in that readout. In terms of the placebo response, the composite endpoint was deliberately chosen as the primary endpoint as it controls better for placebo response. It's very difficult for a placebo patient to achieve resolution by themselves on both on fibrosis and all the clinical endpoints of MASH. Therefore, that was why that placebo rate was chosen. Really I'm not going to speculate on what the placebo rate will be after an 18-month trial versus a 6-month trial, but certainly it's our expectation that having that composite endpoint does help mitigate any fluctuation in the placebo rate.

Yes, okay, thank you so much. We will now go to our last question, and that question comes from the line of Jason for Andy Chen from Wolfe Research. Please go ahead, your line is open.

Hi, thank you so much. This is Jason taking it for Andy. And we just wanted to ask another question about GLP-1. And do you guys think the baseline GLP-1 subgroup is large enough to meaningfully assess whether Lanifibranor provides incremental histological benefits on top of the therapy? And how would that sensitivity analysis be presented?

If you could provide some color on that, thank you. Yes, so first of all, a clarification, the GLP-1's drop-ins that were allowed in the trial were not at the MASH dose. So they were at a lower dose, so there should be no histological impact of the GLP-1, on the GLP-1. So I think that in terms of doing a subset analysis So I think that answers the question that we don't anticipate that there should be a histological effect of the GLP-1.

Jason, would you like to add to that? No, I do, Andrew. Just, Andy, a good question. Just referring you back to earlier in the Q&A around the sensitivity analyses and that this is a question, the form of the question. How is it that other therapeutics that are dropped into a late-stage clinical trial may affect the primary endpoint? This is routinely handled in Phase 3 trials, not in the primary endpoint. Not only outside like in atopic dermatitis and use of steroids, but also within MASH. So the sensitivity analyses that we'll run are completely routine and standard for a Phase 3 program facing those kinds of questions. Got you. Thank you.

Thank you. There are no further questions at this time, so I'll hand the call back to Andrew for closing remarks.

I want to thank everyone for joining today and for the questions. We are, you know, Inventiva at an inflection point right now. We are very excited to be approaching the top line results in Q4 this year, and the potential to bring a therapy forward for a large patient population with a large unmet need and bring a new therapy option. So thank you everyone for your interest and we will see you the next time we talk will be on. So thank you.

This concludes today's conference call. Thank you for participating. You may now disconnect.

This live transcript is auto-generated without human intervention or review.

Well, thank you for joining me today at this fireside chat with CEO of Inventiva, Andrew Obenshain; and the CMO, Jason Campagna. I will do a quick disclosure from Morgan Stanley. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Without further ado, let's get started. Andrew, before we get into the details, could you give us a brief update on where Inventiva stands today and what investors should understand about the company as you approach a very pivotal Phase III readout?

Thank you. And those last words are the keywords. We are approaching a Phase III readout for our sole asset, lanifibranor, and we've guided that, that readout will happen in Q4. So it is imminent. And for those of you that don't know Inventiva, we are a single product company based in France, and lanifibranor is our lead product. It is a product that treats the disease of NASH, which is 1 disease, but that has 2 disease drivers and lanifibranor addresses both those drivers. Let me just give you a little bit of an overview of NASH.

NASH is liver disease and it's the second leading cause of liver transplant in the U.S. There's 2 drivers of disease. There's the scarring of the liver itself, the scar deposit and the lack of scar dissolving and that can progress up until cirrhosis and it can be death sentence if you get to cirrhosis. But it's really driven by metabolic dysfunction, by dyslipidemia, by sugars, by adipose tissue health. And the existing therapies on the market right now really address one of those 2 drivers that either address the liver directly or they address the metabolism. There's no therapy that actually does both. And lanifibranor is really the first that addresses both. And we were very excited to see our readout in the Phase II, which is published in the New England Journal of Medicine, which showed the leading oral efficacy in this disease with an 18% reduction of fibrosis. We're looking forward to try to duplicate that in the Phase III.

That's really super interesting. And you've talked about this kind of dual mechanism for lanifibranor. MASH is often thought of primarily as a liver disease, and you described it slightly differently. So why does understanding MASH as a systemic metabolic disease MASH when you think about how you're going to treat it?

So the -- if you address just the liver, you are addressing just 1/2 of the disease. You're not addressing both. And there's a -- there's been some studies that have shown that you could give a patient the best liver drug that exists, which is a liver transplant, but a healthy liver into a patient with MASH. And within 5 years, they will all have MASH again. And about half of them all have fibrosis because you haven't addressed the metabolic dysfunction. So in order to really get at a long-term solution for disease, you need to be able to address both, and that's what lanifibranor has the possibility of doing.

So with that in mind, like what is fundamentally different about lanifibranor's pan-PPAR mechanism? And why do you think that it could like why do you believe that difference matters clinically?

I'm actually going to hand that over to Jason.

Yes. So we've known for a better part of 25, 30 years now that the PPAR pathway, alpha, delta and gamma are generally metabolic reprogrammers. They manage sort of the state of energy metabolism in an organism. So you think about glucose production, adipose tissue function, energy metabolism, et cetera. The pathways are very clear on what PPARs do. What's new is that as Andrew was leading to that in the last decade or so, since really Intercept came on the scene with the very first attempt at getting a drug approved in NASH, we've gone from thinking that this is primarily a liver-centric or liver-dominant disease. And it's more that the liver is sort of one organ manifestation of a larger metabolic problem. It's an important organ, and it's one that's really severely affected. But when you think about a drug like lanifibranor that can target multiple nodes or axis in this pathway, it makes a very compelling argument that you may have a really better way to get control of both the intrahepatic and those extrahepatic drivers. It's not the only way to do that, but it's certainly a very compelling way to do it.

Okay. And so there are already 2 therapies approved and on market that got a significant amount of clinical data attached to them. Do you think there's still a need for additional MASH therapy?

So absolutely. So the -- it is the market is actually being built in front of us. If you go back a couple of years, there was a question about whether or not there was a real market for F2 and F3 treatment. And now we have 2 therapies that have shown actually tremendous progress in proving that, that market exists. And we have actually built a company in Inventiva with the people to actually go and bring lanifibranor into this growing market as well. Again, these 2 therapies that are on the market, they address either one element of disease or the other, not both. They either address the liver aspect of it or the metabolic aspect, but not both together, and that's where lanifibranor really can make a difference.

And so what do you think the future of MASH treatment is going to look like?

So I think that right now, there's a greater understanding of the need to treat both of these elements, and we're going to see a lot more combinations. There's a lot of more people on GLPs right now, combined well with the GLP-1. We'll actually in our trial, have a number of patients actually on a GLP-1. And so physicians are going to be looking to do those combinations going forward.

And so you've touched on GLP-1 therapies. I think the number of people that are on it, both kind of prescribed but also DTC, and it's really transforming the obesity and metabolic medicine landscape. Do you think the emergence of GLP-1 change the opportunity for MASH-specific therapies like yours?

Well, I think there's a couple of elements in terms of the answer to that question. So the -- in order -- so the GLP-1s have an impact on MASH. But in order to have an impact, you have to be on a higher dose of GLP-1 and you have to be on it for the course over a year before you see a difference. So certainly very useful in terms of treating the disease. But if you have a patient that has F3, for example, so that's a patient that's pretty close to cirrhosis, you want something that's going to act fairly quickly. In our Phase IIb, we showed an effect after 6 months. So I think it's going to be unlikely that physicians are going to really want to wait a full year for effect with the GLP-1, especially for an F3 patient.

And so working through one of those PPAR pathways, actually weight gain is a sign of clinical efficacy. And so you've seen that in some of your trials. How do you think about lanifibranor's weight profile in the treatment landscape that's increasingly focused on kind of weight loss?

Actually going to hand that over to you, Jason.

Yes. I think it's a fair question, but it gets, I think, to the core of what we're trying to accomplish. So I just step back a little bit. We knew for a long time that bariatric surgery, if it's effective at weight loss, can also be effective at improving NASH. So you look at histology, whether it's NASH resolution or fibrosis, we knew that bariatric surgery can do that. So GLP-1s have clearly changed that landscape. The point is that it changed in one very particular way, weight loss through the GLP-1 pathway, muscle, et cetera, does appear to be resetting a lot of that programming that's a problem. That's a very good thing.

With lanifibranor or the weight gain that we see actually has nothing to do with that pathway. It's really around a PPAR gamma mediated effect, which is well known and well understood around fluid retention. The impact of that fluid, the goal of the lanifibranor program initially was to show that on the one hand, we can capture all of that biology in a single drug, alpha, delta and gamma. But on the other hand, the drug as designed could lead to a softer gentler gamma effect. And I believe that's what we're seeing. So it's not that weight gain in the form of fluid is unimportant. It's that when you pair that more modest gamma effect with the benefits that a pan-PPAR agent might give you that, that benefit risk might make a lot of sense in a patient population, particularly the later-stage patients where the urgency to treat gets pretty high. So you're beginning to think at that point, not just, oh, you have NASH, but you have advanced fibrosis and you have several risk factors that if left unaddressed, can lead to pretty severe outcomes over a period of time, that urgency to treat makes a drug like lanifibranor with a more, say, muted or balanced PPAR gamma effect with the other benefits that we hope to see in the clinical program make a lot of sense.

And we already touched on there's already 2 assets approved and in the market. Lanifibranor obviously have its clinical data this year and hopefully, it is soon to be on the market. But there is several years, obviously, that the 2 that are already on market have in terms of kind of commercial but also real-world experience. Do you think that lanifibranor is any kind of disadvantage for not being that kind of first mover? Or how do you see this the commercial landscape?

No, I think quite the opposite, actually. I think what this did it is the entry of these 2 therapies on the market has grown the physician appreciation for the need to treat. As you've seen actually this was not something that published drugs were readily available before. So it has, I think, increased the diagnosis, right, that you see more machines and offices that can do diagnosis now. It's actually increasing the patient pool that's under treatment. And as we come to the market with a therapy that can address the multimodal etiology of this disease, we'll have an opportunity to go into that growing market as well.

Let's turn to the exciting data that's coming up. So NATiV3, what do you think you need to see in the Phase III data to confirm and build on the results that you've already demonstrated in Phase II, which was very impressive.

Yes. So in the Phase II, just as a reminder, Phase IIb, we demonstrated an 18% improvement in fibrosis versus placebo. And we believe that if we duplicate that 18% that we have a very successful therapy on our hands for patients. Specifically, if we -- the way we think about this market is that we do a very simple 2x2 grid. On one axis, you have severity, so F2 and F3, right, just before you get to cirrhosis. On the other axis, you have risk of progression. And for that, we use as a proxy diabetes because you have nondiabetics and diabetics. If you have diabetes, you are at a higher risk for progression, you move faster. And we imagine a future where a patient walks into a physician's office and the -- let's say, the patient gets diagnosed with F3 and they have diabetes. We think that lanifibranor is the first product that doctors are going to reach for and they're going to reach for it for 2 reasons.

Number one, you want to pick up the biggest hammer you've got on fibrosis at that point in order for that patient not to go to F4, which can be a death sentence. And we have an effect of 18% versus the competitors that are in the low double digits. So that's the first reason. The second reason is we do address, we do lower HbA1c. We do address diabetes. That physician -- that is one element for a reason that the physician is going to pick up lanifibranor. The other is they're really worried about that patient progressing quickly because they have diabetes. And they know in our Phase IIb, we showed that we can work as quickly as 6 months. So that is another reason to pick up lanifibranor.

Now so we think that, that is the patient -- that is a very natural place for us to start. And then by extension, the physician will think about lanifibranor in those F3 nondiabetic patient populations. They want the biggest hammer and in that F2 diabetic patient population that they want to address the underlying diabetes.

And so what gives you confidence that what you saw in Phase II is going to be reproducible in the NATiV3 study?

Jason, let me hand that to you.

So I think the first begins and ends with the trial design. So NATiV3 is largely very similar to NATIVE in most of the key elements. So very similar, if not identical patient population. We've narrowed it from F1 through F3 to only F2, F3. The baseline demographics are largely similar when you look at the severity of disease and the comorbidities, et cetera. Third, we are treating for longer, which is a good thing given that the mechanism of action of PPARs do take some time. So 6 months was aggressive and early, and we've already seen an effect. But there are transcriptional modulators, so they take time to work. And the underlying biology takes a little bit of time to work on the liver itself. So the 18 months favors both of those. But from a structural program, the trial looks largely similar to what we did in NATIVE, and we're letting it run longer with both doses. I think all of that lines up to give us a fair bit of confidence that if there's biology that's there, we should be able to see it and identify it.

Great. And so we touched a little bit on the safety profile and talking about weight gain and that we see in the Phase IIb results. There have been concerns and given the historical safety with some PPARs. What are you expecting to see in Phase III? Like weight gain we talked about decrease in hemoglobin, peripheral edema. And what are your expectations?

Yes. I'm going to start and I'm going to hand it to Jason. I think when physicians look at this profile, the thing that they think about versus the efficacy where they want to use it. And you bring up some tolerability issues that we have with the drug in terms of weight gain, which is really fluid retention. So there's a class of physicians that have been using pioglitazone, which is another PPAR gamma and it's still 4 million to 5 million scripts a year, especially with endocrinologists who are very familiar with how to handle this type of profile. And they have -- and there's no concerns in terms of the management in their minds because they -- and they look primarily at the efficacy.

Having said that, the fluid -- I'm going to go ahead and take this. I'm sorry, Jason. If you take a look at the fluid retention, which is what leads to the weight gain, it's mechanistically understood, it's relatively modest, and it can be managed. So mechanistically, as I said, pioglitazone has a PPAR gamma, physicians are comfortable with it, mechanism, modest or slightly attenuated version. We have about 80% PPAR agonist versus pioglitazone, which is not 100%. So the edema that you see with pioglitazone, we have a more modest amount than pioglitazone.

And then lastly, if you actually give a patient SGLT2 or loop diuretic SGLT2 when you combine these, that weight gain is totally mitigated due to the fluid being essentially peed out.

And frankly, with the comorbidities that a lot of these patients have, there's every likelihood they may already be on one of these therapies.

There's a very high likelihood, yes.

And so assuming NATiV3 is successful, how do you see lanifibranor fitting into the kind of the future MASH treatment landscape?

Yes. So I think why I talk about that F3 patient with diabetes being a very natural place. I think that if we are able to show that greater than 18% effect size, just we up into the 20s into low 20s, then I think actually the whole market, all of the 400,000 patients that are currently have F2 and F3 physicians care are patients that would -- should consider lanifibranor. So I think it could be -- and these are things that combine very well with the GLP-1, with SGLT2s. So really, you can look at this as kind of the foundation of MASH therapy for the future.

And it's oral, it's very easy to take and a lot going for it. And there's an increasing focus on compensated cirrhosis and that F4 population. How do you think about the opportunity for lanifibranor beyond the F2, F3 population being studied in NATiV3?

Jason, go ahead.

Yes. I think the F4 population is the most rapidly growing segment in the world now. And I think that's a function of 2 things. We're finding patients more frequently, which is great. But because the disease is chronic and it's subclinical, it's often very difficult to detect and therefore, diagnose when these patients are presenting, they're presenting very late in the stage of disease. I think the second driver is that the field has actually matured a fair bit in understanding what cirrhosis really looks like. So there's an anatomic distinction. I mean put a needle on somebody's liver, take it out, you look at it under a microscope, they have so-called bridging fibrosis or cirrhosis. But we also know that the physiology of cirrhosis, which is portal hypertension, actually appears much earlier than the scarring in the liver would suggest. So we now know that there's a proportion of F3s walking around that are late in their disease. Anatomically, they look like an F3. But physiologically, they behave and have the risk of an F4.

That's a problem in the world. That's the so-called urgency to treat, getting a therapeutic. So how we think about compensated cirrhosis is that we believe that in lanifibranor, the mechanism of action by the way that drug works hits on those nodes, those biologic nodes that drive the portal hypertension, the physiology that leads to these liver-related outcomes. So that when we're thinking about designing our F4 trial and the one that we would like to run, ideally, you want to include a population of patients that are F3 that have evidence of portal hypertension, they look exactly the same as the F4, except when you put the needle in the F4, they happen to be anatomically F4, but they're really the same patient. Those are clinically significant portal hypertension.

Right now, the field is very concentrated on being able to identify those patients. There are guidelines that are being put out on that. And then once you identify them, getting them in the clinical trials to methodically test whether or not you have a therapeutic that can avoid liver-related outcomes. We think that with lanifibranor, the mechanism of the drug, we've recently put out some really nice data over the last year or 2 talking about this. But we think that the mechanism of action of the drug strongly suggests that we might have a real meaningful impact there. So it's something we're actually really excited to do and to sort of get on with it. But step one is we got to get through the data first in NATiV3, and then we'll talk about that next year.

And as you said, Jason, it's a growing population, but it's also a population where there is very, very little available to actually treat the patients and the unmet need is significant.

We agree.

And what do you think investors misunderstand the most about Inventiva and lanifibranor today?

So we get a lot of questions about fluid retention, about weight gain. I think what's misunderstood is the physician choice here. The physicians -- the first thing the physician is looking at is the efficacy, right? And they understand how to manage fluid. They understand how to with diuretics with SGLT2, what they -- what the physicians are seeking is really an option with a higher efficacy and really to help those patients not flip in F4, and that's what lanifibranor offers.

I'll be a little bit more philosophical. We've -- recently, in the oncology world, there's been some beautiful data in pancreatic cancer, right, and the KRAS inhibitors. When you look at the company that did that, they had one mission to do that job. I think what people underestimate with Inventiva is that it's a 14-year-old company that was founded by a group of people that had one goal. They were PPAR biology experts. They had one goal. They wanted to make a drug that will solve the tolerability and safety issue that had plagued other PPAR therapeutics, not all of them, fenofibrate is successful, bezafibrate. There are a lot of successful drugs in PPARs, but they wanted to solve that problem and apply that therapeutic to the field of MASH. I think what people underestimate is that we've had people in Inventiva that have been there 35 years since long before the spinout, the inventor of lanifibranor was still at the company until last year. So I think people, although we're new to the management team, the sort of intellectual wiring diagram of that company goes back decades, and they have been on one mission to solve that problem.

I think when you find focused people like that, you sort of get out of their way because what they can do with that is pretty powerful. So I think we're very fortunate. We all believe in our management team that we're sort of the recipients of all of that. We don't want to mess it up in any way, but it's a pretty powerful story.

I mean it's amazing to hear that conviction and that belief in this asset.

Exactly, over a very long period of time. And a very difficult capital environment for the company. I think Andrew and I both joined on the tailwind of a group of people recapitalizing this company in 2024 because they believed in the data and the power of it. But while that company was in trouble, the what we'll call the old Inventiva, those people were still there, still working away in the offices in France and still working on that problem, good for them.

Absolutely. Happy to open it up to the audience for any questions for Andrew and Jason.

Firstly about the additional benefit in a longer follow-up period. Are there plans to follow any of the Phase II patients to gather any other long-term data on them?

You're asking about the Phase II patient population. No. So that trial is long closed and those patients are sort of off the follow-up. But in the Phase III study, we have 2 mechanisms to follow them. After the trial ends at week 72, they can go up to week 96 and remain on therapy for follow-up. And then if they choose, they're all eligible to roll into an active treatment extension that would get them out another 52 weeks. So we have 2 ways in which we can follow both the main randomized cohort and the exploratory cohort, about a total of 1,500 patients.

Well, Andrew, Jason, thank you very much for your time today and joining us at the Morgan Stanley Healthcare Conference. I think it goes without saying that there is an exciting couple of months coming out of the company. And I for one, I'm really looking forward to seeing what is certainly probably one of the most highly anticipated Phase III readouts after 2026. So best of luck.

Thanks.

Thank you, and thank you for having us.

Thanks a lot.

Good day, and thank you for standing by. Welcome to the Inventiva Full Year 2025 Financial Report Webcast and Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, David Nikodem, Head of Investor Relationship. Please go ahead.

Good morning, good afternoon, everyone, and thank for joining Inventiva's Full Year 2025 Financial Results and Business Update. Our press release was issued yesterday evening, and this webcast and slides will be available in the Investors section on our website following the call. Joining us on the call today are Andrew Obenshain, Chief Executive Officer; Jean Volatier, Chief Financial Officer; and Dr. Jason Campagna, Chief Medical Officer and President of R&D.

I would like to remind everyone that statements made during today's conference call and during the Q&A session may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Please refer to Slide 2 of the slides and our SEC and AMF filings for a discussion of associated risks. These statements reflect our views as of today and should not be relied upon as representing our views at any later date.

With that, I will now turn it over to Andrew, starting on Slide 3. Andrew?

Thank you, David. Good morning, good afternoon to everyone, and thank you for joining us. Since joining Inventiva 6 months ago, I've been struck by the depth of scientific conviction behind lanifibranor and the dedication of this team. Today, every resource, every decision and every member of this team is now aligned behind a single objective, advancing lanifibranor towards approval for patients with MASH.

Let me start with our main focus, our global Phase III clinical trial NATiV3. Enrollment was completed in April 2025 and represented a landmark operational milestone for this company. Today, we are updating the expected timing of our top line readout to Q4 2026, reflecting the disciplined sequencing of our clinical and biostatistical milestones. We believe the data from the NATiV3 trial, if positive, has the potential to carry weight with regulators, physicians and most importantly, with patients. And we believe we are running this program with the rigor and precision all stakeholders deserve.

On our pipeline and organizational focus, in the first half of 2025, we made the strategic decision to concentrate all of Inventiva's resources on lanifibranor and MASH. As part of this plan, in Q4 2025, we sold our global rights to odiparcil to Biossil and we may receive up to $90 million of potential regulatory and commercial milestone payments, as well as potential high single-digit royalties on future net sales if approved. While this transaction frees up our internal resources to fully focus on lanifibranor, we are pleased that odiparcil has found a new home where its development can continue, potentially in offering patients with MPS VI an opportunity for treatment.

At the same time, we strengthened our leadership team to align with the level this opportunity demands. Jason Campagna joined as CMO and President of R&D. Martine Zimmermann joined as new EVP and Head of Quality and Regulatory Affairs; and Nazira Amra joined as our Chief Commercial Strategy Officer. We are building towards launch in a lean and targeted way, advancing our readout and NDA preparations while laying the early groundwork for commercialization in anticipation of potential approval of lanifibranor. And the opportunity is real. MASH has been underdiagnosed and undertreated for too long, but that is changing. More patients are being identified, more being diagnosed and entering care. Awareness is growing, screening is improving and metabolic disease is finally getting the attention it deserves.

The numbers tell that story clearly. There are an estimated 18 million people in the U.S. living with MASH, but only around 10% have been diagnosed, and that number has grown by 25% compared to 2024 estimates. Among those diagnosed with clinically actionable F2 or F3 disease, only around 40% are currently under the care of a treating position. So while diagnosis rates are improving and the market is evolving, far too many patients with significant fibrosis remain without the care they need and face a real risk of progression to cirrhosis and liver failure. If our NATiV3 trial can replicate the 18% fibrosis improvement seen in Phase II, we believe lanifibranor could be well positioned as a potential best-in-disease oral therapy with significant commercial impact. Ultimately, our goal is to make a meaningful difference for patients and that is what drives everything we are doing.

I will now turn the floor over to Jason, who will give a brief update on lanifibranor, our differentiated oral anti-fibrotic, and a potential new treatment option that we believe addresses the remaining unmet medical needs in MASH.

Thank you, Andrew. Good morning and good afternoon, everyone. Let me start by reminding you of the mechanism of action and the development pathway of lanifibranor. Lanifibranor is a small molecule designed to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes by activating all 3 PPAR isoforms, alpha, delta and gamma in a balanced manner. This broad mechanism of action is designed to target the hepatic and extrahepatic drivers of MASH simultaneously and in one oral therapy. Lanifibranor was the first asset to achieve statistically significant improvement in the composite endpoint of both fibrosis improvement and MASH resolution in our Phase IIb NATIVE trial, after just 24 weeks of treatment with a favorable safety and tolerability profile.

On the basis of these results from our Phase IIb the FDA granted lanifibranor breakthrough therapy and fast track designations. NATiV3, our pivotal Phase III clinical trial was designed to confirm and extend those findings in a larger, more diverse global population over 72 weeks and is intended to provide the data to enable successful marketing authorization in the United States and Europe. NATiV3 is a randomized, double-blind, placebo-controlled trial in patients with biopsy-confirmed MASH and stages F2 or F3 fibrosis, the core of the MASH treatment population. Those with significant disease burden and a high risk of progression to cirrhosis, liver failure and liver-related mortality.

We specifically chose a clinically meaningful primary endpoint for NATiV3, fibrosis improvement and MASH resolution. And at 6 months in our Phase IIb the 1,200-milligram dose of lanifibranor showed a 24% treatment effect. NATiV3 was also deliberately designed to mirror the patient population of our positive Phase IIb and the real world as it exists today. A meaningful proportion of our patients have type 2 diabetes and other metabolic comorbidities, and a number are on background GLP-1 and/or SGLT2 inhibitor therapies, mirroring the patient's physicians actually see in their clinics, which we believe will ensure that we generate clinically meaningful data to support both NDA and MAA submission.

In April of 2025, we completed enrollment, exceeding our original targets with over 1,000 patients in the main cohort and additional 410 patients with MASH and fibrosis stages F1 through F4 in an exploratory cohort. We anticipate sharing the top line results of our pivotal Phase III trial in Q4 of this calendar year, a moment, I believe, will be significant for the field and for the patients who need new treatment options.

I will now turn the floor over to John for our financial review.

Thank you, Jason. Good morning and good afternoon, everyone. So yesterday evening, we issued our press release with our full financial results for the year ended December 31, 2025. I will focus on the highlights. As of December 31, '25, we held EUR 230.9 million, close to EUR 231 million in combined cash, cash equivalents and short-term deposits. This position was built by 2 significant financing events in '25. First, the execution of the second tranche of our 2024 structured financing in May generating approximately EUR 108 million in net proceeds.

And second, our U.S. registered public offering in November generating approximately EUR 139.4 million in net proceeds. We estimate that we are funded beyond our anticipated NATiV3 readout. Based on our current operating plan and cost structure, we estimate that our cash runway extends to the middle of Q1 2027 and to the middle of Q3 2027, assuming the full exercise of our tranche 3 warrants, which could generate up to an additional EUR 116 million. We confirm this way the cash guidance provided earlier. Our R&D expenses for the full year were EUR 87 million, primarily reflecting our pipeline prioritization and, to a lesser extent, the completion of NATiV3 enrollment in April 2025.

Marketing and business development spend increased to EUR 5 million primarily due to expenses related to a planned pre-commercial investment as we prepare for a potential launch of lanifibranor if approved. G&A expenses of EUR 47.9 million include approximately EUR 20.3 million of noncash share-based compensation tied to the governance and organizational transition we implemented this past year.

I will now turn the floor back to Andrew for closing remarks.

Thank you, Jean. Inventiva enters 2026, well-funded, operationally focused and ready for a consequential chapter in this company's history. NATiV3 is fully enrolled. We've built a leadership team with deep medical, regulatory and commercial expertise, and our regulatory and commercial readiness work is progressing in parallel. Our anticipated top line readout in the fourth quarter of this year represents a genuine inflection point, not just for Inventiva, but for the millions of patients living with MASH, who still have no adequate treatment options. We are truly executing with the discipline and urgency this moment demands.

Thank you for joining us today. We will now open the floor for questions. Operators, please go ahead and provide instructions for the Q&A session.

[Operator Instructions] We will now take our first question. And our first question for today comes from the line of Seamus Fernandez from Guggenheim.

Just a few quick questions. First, can you update us on how the performance of the trial has been in terms of dropouts? I know that there were some requirements from the tranches that were coming in that were successfully completed. But just wanted to get a sense of where the dropout rate was as you were kind of wrapping up enrollment.

Second question is, can you help us understand how you're thinking about the performance of the 800 versus the 1,200-milligram dose in terms of both weight gain and then ultimately on fibrosis? Is the sort of change from a more typical 12-month endpoint to the 18-month endpoint geared to have the 800-milligram dose catch up to the 1,200 but also manage the potential tolerability or weight gain issues?

And then to the last question is just what you're seeing in terms of the overall market interest. Madrigal continues to see very strong uptake in the U.S. How are you thinking about the opportunity to compete with Madrigal? What do you think is the threshold necessary? Andrew, you mentioned 18%. Just interested to know if you think 18% is the threshold where the impact is going to be substantial or is that more reference to the powering of the study?

So, Morning, Seamus. Thanks for the questions. I'm actually going to take your third one first and then hand the first 2 over to Jason. So yes, just to be really direct, we think that if we replicate the Phase II trial and have an 18% effect on a fibrosis, we have an excellent drug. That is the clearing efficacy that we need for in order to have a very attractive market opportunity. We continue to see a lot of market growth, thanks to the entry of the 2 approvals and a lot of awareness around MASH. And there still continues to be unmet need, especially we see in that F3 diabetic patient population, where we think there'll be a very good entry point for lanifibranor.

And then at 18% of fibrosis effect with our HbA1c lowering, we have a very good profile for that. Let me then turn the question over to Jason first on the drop-offs and what we've last discussed publicly there. And then the second question about the 800 catching up the 1,200 dose.

Seamus. So let's take the first one. So you are correct. As part of the structured financing from 2024, there were covenants in there around the release of follow-on tranches that the early termination rate for the trial needed to be below 30%. That number was selected because the original powering analysis from the trial was built allowed for up to a 30% dropout rate. So that was the metric that was used, and we have disclosed publicly at the time of both the first and the second tranche release, which would have been in April of 2025, that we were below that threshold.

I think now that we're tightening the guidance to Q4 of this calendar year, I think we were able to confirm we are well within that range and feeling quite good about where we've landed and are reaffirming that the trial is well powered to detect the primary endpoint with the size of the trial that we have and the early termination that we've seen.

So the second question you asked about the 2 doses, I think you're landing sort of in the right mixture of elements that are important to us. So we agree with you that in theory, with additional time just because of the way PPARs work and the biology of the liver that that 800-milligram dose will have time to sort of catch up to the 1,200. It was already quite a good dose back in NATIVE, as you recall. But 6 months is relatively thin for a PPAR, which is a transcriptional modulator to sort of do its work. So the idea that you could see a deeper effect with that 800 dose at 18 months, it's very reasonable.

But I think where you're landing around the potential dose responsiveness of the tolerability concerns, that is also very important to us. So take weight gain, which you mentioned. Weight gain is a traditional PPAR gamma mediated fluid retention event, and we know that, that fluid retention is highly likely to be dose dependent just from what's been shown with other PPAR agonists and our own data from NATIVE. So we think that potential to have really strong efficacy with both doses, which we were able to show in NATIVE, but may have a different tolerability profile at the lower dose could be meaningful for patients. So it's our hope that both will be positive, and we'll have that opportunity to discuss that with regulators.

Our next question comes from the line of Yasmeen Rahimi from PSC.

This is Dominic on for Yas. The first one, we know that NATiV3 is a very large data set. As we're getting closer to top line data in 4Q, what are some of the quality control, I guess, protocols going on in the background to analyze the biopsy samples and what procedures are in place to ensure timely and thoughtful assessment of these biopsies?

And then our second question is, can you just talk or help us understand, I guess, how you have how -- if you had any recent safety monitoring committed? And are you seeing anything on a blinded basis on the safety profile? Any color there would be helpful.

Good morning, Dominic. So 2 questions. Let me take the second one first, and the first one over to Jason. Just on safety monitoring, there are periodic monitoring committee meetings every 6 months. You would know if they had said anything. Other than that, we really can't say anything about those meetings. Go ahead, Jason, on the biopsy.

Yes. Thanks, Andrew. Dominic, so quality control and biopsy. Let me start by saying that the team we have here is outstanding. The clinical operation, the clinical development team have been immersed in the world of MASH clinical trials for the better part of a decade. So this is something that they know well and we carried that expertise forward. So you could think of quality control biopsy around 3 issues. Are we hurting the patient? Meaning at the bedside, are we doing the right things. Second, are we capturing the biopsy according to standard practice? So that's the length of the biopsy, the overall quality of the core, if you will. There's measurements and things that sort of go in and say check or not check. We have reviewed all of those and continue to do so right up until when we get to last patient, last visit later this year.

And then lastly, finally, when the slides are sectioned prior to going off and being read, there's a quality control set there that looks at what actually gets made on to the slide. Afterwards, at that point, we are obviously blinded to all of that information. But there is a quality check in terms of are the reviewers, the readers staying on time and on track reading biopsies in the paired matter that's specified both in the protocol and the analysis plan. So I like the teams that we have in front of it and more importantly, I think that they are doing exactly the right work to keep us on track.

Our next question for today comes from the line of Ritu Baral from TD Cowen.

I want to drill down a little bit more upon final powering. You guys disclosed the over 1,000 final patient number. I think it's 1009 and the 90% powering. What's the effect size that, that powering is for on the primary combined endpoint? And what are your expectations for potential movement around placebo of that, I think it was 7% at the 6 month upon the final primary endpoint? And then I have a follow-up on market expectations around that F3 diabetic population that was mentioned.

Thank you, Ritu. Jason, why don't you go ahead and answer that question?

On the first one, we are not guiding to the actual effect size, but I can reiterate for you and for everyone what we have been saying. So first, we are with the sample size of over 1,000 patients. We are powered to over 90% on a primary endpoint of the composite fibrosis improvement 1 stage or more MASH resolution. That one has a higher placebo response than we showed in NATIVE, which as you know, was 7%; and two, a smaller treatment effect than we showed in NATIVE data about the 1,200 milligram dose. So that means the overall effect size that we are powered to is smaller. So a much more conservative view than the actual data that we showed in the Phase II program.

We just talked earlier with Seamus that, that alongside our comfort with the early termination rates we have, we feel very good that the trial is structurally sound and that will give us an answer to the question one way or the other. Did lanifibranor work first at the 1,200-milligram dose? The testing is hierarchical. We can't get to the 800, unless you went on the 1,200. But that is the core question. We think the trial was well set up to deliver an answer to that question that is well powered and highly confident.

I think to your second question around placebo response. The individual endpoints of fibrosis alone. I think everybody on the call knows this, fibrosis alone improvement or MASH resolution alone can be quite noisy. It's not clear after all these years of study why that is, but we do know that they're noisy. On the other hand, the composite endpoint, the primary endpoint of NATiV3, are with us and other sponsors have shown that, that endpoint is much less prone to placebo response. And that makes sense, Ritu, biologically, right? You have in 1 patient, they may on a placebo response move their fibrosis stage by 1 point or more, but the idea that they can also resolve their MASH spontaneously.

What that 7% tells you was that in the wild, in the real world, that's incredibly uncommon and that makes total sense with the actual way that patients walk in. It's unusual if you leave them sort of sitting along without treatment, that both of those things will get better on their own. So the placebo response there actually reflects, we believe, the underlying biology, and it should remain very low. We've seen it by precedent, and it's our expectation for the trial that we're running.

Very helpful. And then, Andrew, a question on how you guys and your own market research is viewing that F3 diabetic population. Do you have an approximate patient number? How is the diagnosis rate in that population changing versus the overall MASH population given the ADA focus on MASH and its messaging to diabetologists?

Thanks for the question, Ritu. So in terms of size, there's about 375,000 patients total F2, F3, in under treatment of care right now. The largest segment is -- one of the largest segments is that F3 diabetic patient population, being 55% to 65% of the patients are diabetic, and about it splits roughly 50-50 in our market research between F2, F3. So that patient population is quite a large patient population overall. In terms of growth, we don't have the granularity down to that segment. However, I would just know anecdotally that F4 is one of the fastest-growing segments. And I think the diagnosis rates are increasing quite a bit overall for F2, F3, F4, just to the number of entrants into the market. So they are growing a minimally proportionate with the market in that segment.

To that point, Andrew, can you tell us of the 410 expansion cohort patients, how many are F4. Do you know at this point?

I'll pass that question.

Yes. Confirming you're talking about the exploratory cohort, correct?

The exploratory cohort, yes.

We do have F4s in that cohort. They would have screen failed in that case, by histology, potentially other lab values for the actual main cohort in NATIVE. So they represent a sort of range of F4 from. They're all compensated by definition, meaning they have no clinical outcome events, decompensation events. But the range of severity with portal hypertension can be from none to evidence of clinically significant. And those -- that data is going to be quite interesting to us. We're not yet guiding on when we'll have an opportunity to get those data out. It's unclear right now if we have them at top line per se, or in the weeks that follow it in one way or another. But I think as we get closer to top line data, we should be guiding on that more tightly.

Our next question today comes from the line of Thomas Smith from Leerink Partners.

Just wanted to follow up on that F4 population. And I know you're capturing some of those patients in the exploratory cohort. Can you just expand a little bit on what you hope to learn from that exploratory cohort and how you're thinking about planning for the outcome study in F4s pending the NATiV3 data and perhaps how you're thinking about perhaps how some of those plans could change. We know we're going to get F4 outcomes data for Rezdiffra also in 2027. So some interesting timing around that data set relative to when you're planning on starting this F4 outcome study.

Thanks for the question, Tom. Jason, go ahead.

So there's a lot there. Let me make sure I get it all for you. So one, just in general, what are we expecting to learn from that cirrhotic population in the exploratory cohort. First, above all safety of lanifibranor in that population. Clearly, right, if you're going to bring in a new therapeutic into a more, let's say, sicker population, you want to obviously want to have safety headroom to do that. So approximately 75 patients we have in that cohort safety above all else.

Second, it's not that, as you know, that cohort is not tracked systemically -- systematically, excuse me, for efficacy. That being said, we do anticipate having data of things on like LFTs, transaminases and other things that would point directionally towards whether the drug is biologically active. So really a pharmacology question, very important. We have done hepatic impairment studies with the drug, but looking at it in a real world and a clinical trial would be incredibly helpful.

And I think lastly, it will give us a sense in our own hands of how those patients progress over time to later-stage disease. You could read about it, you can model it, you can look at other people's trial, but in your own trial we will see how many of those patients go on to actually have liver related or other events. And that will be incredibly helpful as we think about powering and sizing of an outcome-driven trial, which is what we're right now calling NATiV4, for lack of a better term. But make sure that, that gets to your question, Tom, on the value of that cohort to us?

Yes, that's helpful.

Great. So now look, you know the Madrigal data coming. I think yet we acknowledge that. We agree. I think our view is that positive data, if Madrigal were to show it, would only be helpful for the field period, full stop. The idea that we have now finally shown that the surrogate endpoint does correlate with clinical outcomes would be an enormous one for the field. Look no further than what happened in the cardio renal division with proteinuria in the last 6 years. Proteinuria was issued as a surrogate in 2019. I have 5 or coming 6 approved therapeutics for IgAN, that's an enormous win for patients. So we expect something like that would hope would happen here.

But clearly, that would influence our thinking about how we think about populations and the ones that are most likely to develop liver-related outcomes because we want to get more of them since we know that the sort of door is open to show that the histology will map to clinical outcome.

Our next question comes from the line of Michael Yee from UBS.

I have [ 32 ] myself. First question is on weight gain, can you remind or confirm the views that based on the phase II also, I think what you're sort of said in the ongoing Phase III that there is some initial weight gain, but that it plateaus and that you don't really see anything beyond a modest increase in some patients, at least in the phase II, and that plateaus and that was initially seen in the Phase III, and therefore, no concerns.

The second question is, is there any view that either because of other drugs or because of longer time duration of 18 months versus 6 months here that, that could actually come down in some of those patients or at least come back down to baseline, is that possible?

And then the third question is around getting the regulators comfortable with that, what I guess fluid retention effect in some patients and that there would be presumably no at least initial cardiac imbalance in any of the arms that you see and which you'll be able to talk about no imbalance in any cardiovascular events numerically or any SAEs of that nature when you disclose the data in the fourth quarter?

Mike. You were a little soft, so I'm just going to repeat some of it. So there was a question about does weight gain indeed plateau and number one, if in the Phase II. Number two, does that weight gain -- is there a chance of that weight gain would actually go down in the Phase III, either due to concomitant medications or longer treatment? And then number three, some of the weight gain do -- if the weight gain is due to fluid is there any concerns about a cardiac imbalance in the trial. So for those 3 questions, I'll hand it over to Jason.

Yes. Mike, good to talk to you again. So we have previously said and we'll reaffirm it here that the data that we have previously shown from the blinded look at NATiV3 back in September of 2024, and that we also disclosed at that time the FASST clinical trial in systemic scleroderma, which was a year trial with treatment of lanifibranor same doses in NATiV3, 800, 1200 milligrams, that the weight -- the fluid retention weight gain appear to plateau. I think we don't have any additional information to guide on that publicly, but I think that is what we've seen in both of the clinical trials so far.

I think second, do we expect the weight to come down? It's well possible. I think there are a couple of factors at play. Take the LEGEND study, for example. We show that when patients are given SGLT2 inhibition in parallel with lanifibranor that there's almost no weight gain at all. There are many patients in the trial that are on SGLT2 inhibition and do not have the number for you off the top of my head. And we know that patients can be started on those therapeutics for management of diabetes or any other reason. So it is entirely possible and reasonable to believe that if patients are getting SGLT2 inhibitors or other diuretics to manage blood pressure, et cetera, that, that weight gain either the fluid retention, could be blunted or resolved so that the final landing spot, if you will, for any patient, might be lower than the peak weight gain that they had in the trial. But I think we'll see what the data show.

Lastly, in terms of regulators, I think I can't speak for the FDA, but I can only speak to what I've read of everything they've put out. The fluid retention is a known phenomenon with PPAR gamma agonism, the thing about lanifibranor is it was designed to be different than other PPAR gammas, and we'll see what the data show. Our view is that it is a very different type of PPAR agonist. But that being said, the PPAR gammas is a known effect. It is on target. It is not idiosyncratic in any way. So FDA has shown with labeling and other work that they are comfortable with fluid retention, I think you're hitting on the right point, the cardiac. And as we've talked about and guided publicly over the years, we are not seeing congestive heart failure as a clinical issue in our program. It doesn't mean that we don't follow it.

And it doesn't mean that you're thinking about how fluid retention may lead to that. That's certainly in the PPAR labels today, the gamma agonist, but it is just not something that we are generally seeing in our program, but we will be paying careful attention to it, and it's a dialogue we'll have with FDA.

[Operator Instructions] Our next question comes from the line of Ellie Merle from Barclays.

This is Jasmine on for Elie. So as kind of a follow-up to Ritu's question. You talked about the overlap of MASH in type 2 diabetes as a segment where lanifibranor can be particularly attractive. But do you have a specific bar for what competitive data would look like in this population? And then specifically, how many type 2 diabetes patients do you think have undiagnosed MASH, and how do you plan to work to increase the diagnosis in this population and unlock that segment?

So I'll take those 2 questions. First of all, just the diabetes and overlap with MASH, it is enormous, right? And there's -- I think there's about 18 million patients in the U.S. with undiagnosed MASH. At least half of those or more have diabetes at it's obviously way, way more than 375 under the treat or care. The way we see the market evolving is we've seen since about 2004 that market has grown about 20%. So it's clearly quite robust growth, and we do anticipate that to grow nicely. We, as a company, probably will not be pushing diagnosis, at least initially, there are enough patients coming in that we can focus on the patients being diagnosed -- the existing patients being diagnosed. That would obviously, maybe a later marketing strategy would be to actually increase diagnosis.

And then your first question about -- I'm sorry, I forgot your first question already.

Just if you have like a specific bar in that population for what competitive data looks like?

Yes. So the -- in terms of competitive data, the way we look at this is that the differentiated profile that we have is we work both on the liver and we're extrahepatic. We work on the body and we work on the liver. So we have direct anti-fibrotic effect. Again, as I said, that an 18% effect size, if we duplicated that in the Phase III trial, we feel it's a very competitive drug. And then the other thing we'll be looking at is HbA1c lowering, which was on average across the whole patient population, diabetic and nondiabetic in the Phase II, with just over 0.5 point, that would be an approvable diabetes medication years ago.

So that combination of HbA1c lowering, combined with triglyceride lowering, HDL raising and the fibrosis effect, we think, has an extremely attractive profile for that diabetic F3 patient.

Our next question comes from the line of Lucy Codrington from Jefferies.

Just one left, please. Regarding the confirmatory trial, just wanted to confirm, do you have an understanding with the FDA in terms of what underway means when it comes to granting accelerated approval? Is it enough just to have started that trial? And does this need to be by the time you file or by the time you get to approval? And then related to that, is starting that trial included in that mid 3Q cash runway with the third tranche of warrants?

Yes. So yes, it is included. Starting that trial is included in the cash runway of that mid-Q3 runway. Jason, you want to talk about what's necessary for the trial?

Yes. Lucy, I think you have the broad brushstrokes of it, right, but just something on the language. So accelerated approval is only at the time of the review. What we're looking to get is conditional approval under Subpart H, which is you've got marketing authorization and then the trial, as you note, confirms your surrogate and then you get full approval. Whether accelerated is only a question of how long it takes the FDA to actually review the file.

With that, I'm just trying to make sure that we're all clear on that, that we -- you have the broad brushstrokes, right? But the individual rules are discussed with each sponsor at the time of the pre-NDA meeting and then during the mid-cycle review. But the general framework is you need to have most of the trials structurally in place, protocol approved at the time you were filing the drug and it needs to be moving on the definition of moving is going to be something FDA will define for us. We will be prepared. We have our CROs selected, the protocol is approved, may even have sites open. All of that is in the future.

But at the time we file, we will meet the FDA position of trial meaningfully underway. And then at the mid-cycle review, you need to show continued progress on that. So they will check again that made a much more detailed look around enrollment nerves, site activation curves, et cetera. Again, each sponsor has their own detailed agreement with FDA on that, and it is our plan, of course, not only to have those conversations, but to make sure that we're meeting those requirements. So that when we are offered if we're fortunate enough to make it there, and we offered, the conditional approval, that trial will be well underway at that point.

Got it. Thank you, and thank you for clarifying on the terminology.

Our next question for today comes from the line of Annabel Samimy from Stifel.

This is Jayed on for Annabel. Congrats on the progress. Just 2 for me. The first one is around the use of background GLP-1 in the trial. What are your expectations on the potential impact of having that background GLP-1 use on [ lani ] effect size of those patients? And my second question is around the AIM-MASH tool that was nearly FDA qualified as a supportive tool to help with histological assessments. Do you have any plans to maybe leverage that to control or minimize variability?

Yes. Thanks, and thanks for the question on the impact on the lani effect size based on background GLP-1 and the tools. So go ahead, Jason.

Yes. So in confirming we do have, and we've previously shared that we have about 14% or so of the population in NATiV3, that's across both cohorts, that have background GLP-1 use at the time of randomization. That could be semaglutide, older drugs, liraglutide, dulaglutide, et cetera. So it's not only limited to the modern GLP-1. And I think its effect on treatment response should be minimal, and that should -- it will sound tongue in cheek, it's not intended to be. It's because that when you enter the clinical trial independent of what drugs you're on, whether you've lost weight by any other measure, independent of a GLP-1, you're entering the trial issue have that F2, F3 disease with active MASH.

So whatever it is, one, those drugs are not doing it for you or your lifestyle modifications; and second, that the doses that we're using are really the diabetic doses. So they don't -- they are not anticipated to have much of an effect at all. We're simply seen that in the clinical trial data. I think to the second question about the tools, are you talking about PathAI specifically or just more general non-invasives?

Yes, no, it's the PathAI tool.

Yes. It's an interesting idea, right? But if you -- looking at it really simply, what PathAI lets you do is substitute one human pathologist for a digital pathologist and then you need a second pathologist to read. It's still the same idea of 2 plus 1 consensus. In this case, 1 of the 2 is PathAI. It's interesting. It's not something that in NATiV3, we anticipate taking much advantage of. But it is something we're thinking very closely about for NATiV4, potentially using that as the -- in the exploratory cohort presently from NATiV3 to see how we may be going to pull more data out of those patients that happen to have a biopsy.

Our next question for today comes from the line of Rami Katkhuda from LifeSci Capital.

I guess can you remind us of lanifibranor's FC and F2 versus F3 patients in the Phase II study and how those differences may impact expectations for NATiV3 just given the higher proportion of F3 patients enrolled?

Go ahead, Jason.

Rami, just to qualify, you want the proportion of patients in NATiV2 or the responses of the F2, F3?

The responses, please, between the F2s and F3s.

The sample sizes are simply too small to break out what we have done. We think the analysis that's more helpful, it's in our corporate materials, is that when you strip away the F1s in that trial. You get down to about 188 F2, F3 across all 3 arms. You can see that the effect size actually slightly goes up. What we guide to is that it remains unchanged. So the drug seems to work equally well in more advanced fibrosis in patients with earlier disease. So you're not getting much of a free glide on those F1s, if you will.

I think second, when we look at NATiV3, as Andrew talked about earlier, this is a contemporary MASH market. The majority of patients showing up and clinics today that have F3 disease, will have diabetes. So we think that aligns pretty well with the outside world. And we're pretty comfortable with what we've seen from our Nature publication back in 2024, that the drug not only works equally well in earlier and late-stage disease, but the adiponectin levels actually go up equally well across all cohorts and it's that adiponectin that's really driving, we think, well correlated with the clinical response. So we like where we're landing with NATiV3 and the likelihood of efficacy in both those F2 and F3 patients.

And as a reminder, we're stratified by fibrosis stage and diabetes and NATiV3, so we're going to cut those data in a number of different ways to sort of get where you're headed with your question.

Our next question comes from the line of Srikripa Devarakonda from Truist Securities.

This is Anna on for Kripa. So 2 questions from us. First, looking ahead a little bit in terms of the MASH guidelines, would you expect an update on the MASH guidelines this year? And how are you thinking about getting [ lani ] into the MASH guidelines? And then second question, in terms of cash, what kind of needs to happen for you to have access to that third tranche? Is it based on kind of Phase III success only? And are you looking at any other non-dilutive sources of funding such as partnerships?

Thanks for the questions. So on the MASH guidelines, I think we will wait -- we need to get data first before we have any conversations about putting lanifibranor into the MASH guidelines. On cash, the tranche 3 is a positive endpoint, and we hit a positive endpoint in our trial, and then when those 77 million shares of EUR 50 become exercisable, and the investors have 45 days to exercise them. So that's how that mechanically works. So positive trial equals cash coming in, so as long as the stock price is above the EUR 50. We are always looking for ways to increase our cash runway. And we've obviously in a very strong cash position right now.

In terms of partnerships, right now, our plan is to commercialize lanifibranor ourselves. Going forward, we think that there's plenty of access to capital, either in the equity markets or other kind of capital sources that we don't necessarily need to partner lanifibranor.

Our next question comes from the line of Sushila Hernandez from Van Lanschot Kempen.

Could you elaborate on your regulatory and commercial infrastructure? What steps are you taking to act with speed once the data is here, also considering your cash runway?

Yes, good question. So yes, so we are being very careful stewards of our capital right now before data. So a lot of -- the regulatory team is fully staffed, and I would include the quality team on that, too, because that's necessary, to make a really good filing with the FDA. So we have invested. We've increased the size of that team and the talent on the team in the course of this year.

From a commercial standpoint, really focused on strategic commercial execution. So being led by Nazira Amra, really focused on market access, the market research. I'm going to include in the broad commercialization medical affairs there. So the strategic role that won't really set us up for success in the future. We will not staff up aggressively in commercial until we have positive data.

This concludes today's question-and-answer session. I will now hand the call back to Andrew Obenshain, CEO of Inventiva for closing remarks.

Thank you so much. Thank you, everyone, for joining the call this morning. We certainly have an exciting remainder of the year coming up for Inventiva, and we look forward to engaging with you all as we go forward. Thank you.

This concludes today's conference call. Thank you for participating. You may now all disconnect.

Great. Welcome, everyone. Very excited to have Inventiva here with us today ahead of a very exciting year for you into a Phase III readout. We're getting a lot of investor questions on this. So a lot to talk about today. I'm Ellie Merle, one of the biotech analysts here at Barclays. Joining us from Inventiva is CEO, Andrew Obenshain, I'm so sorry if I butchered your name, Chief Executive Officer; and Jason, Chief Medical Officer. Thank you both so much for joining us today.

To begin with, can you give us an overview of lanifibranor and the design of your Phase III trial as we head into the data later this year?

Yes. So maybe I'll start at a high level, and I'll hand it to Jason for the Phase III design with lanifibranor. So we are a one-asset company. Lanifibranor is a pan-PPAR agonist that we're developing in a Phase III study for [ MASH ]. We -- it is a product that's been in development for quite a number of years. It's a rationally designed molecule designed to design out the liabilities of former PPARs. So learned from Actos and Avandia, for example, and designed out the liabilities by making a more moderate gamma binder. And then also it's a balanced PPAR. Another insight was that these PPARs are networks. And if you affect one, you affect them all, and therefore, you want to hit them all in a balanced way.

Before we go into the Phase III, I do want to comment on the fact that we were required by the FDA to do quite an extensive toxicology work, 2 years in animals that were -- that was due to the past PPAR experience. Those came out that we press released those. Those actually had Actos and Avandia, going through those. They would not have survived. And we showed that we had a very good tolerable profile, went into the clinic. We've done 5 or 6 Phase I trials. We had a positive Phase IIb trial published in the England Journal of Medicine. So quite an extensive background before we even got into this Phase III. But maybe, Jason, you can talk about then how we've started...

That's great. As Andrew said, NATiV2 was a successful Phase IIb trial, published in the England Journal of Medicine now about 5 years ago, 2021. I think in that era, the excitement, it sort of lost 5 years later, but it was the first drug ever in NASH to not only show a meaningful effect at 6 months, but it had done so on a dual co-primary endpoint of both NASH resolution and fibrosis improvement in the same patients. So NATiV3 just builds on the strength of that study. NATiV3 is largely similar in many cases identical to NATiV2. Obviously, it's longer. It's 18 months, but it's still the same basic construct, 3 arms, 1:1:1, 2 doses of lanifibranor against placebo.

The primary endpoint is somewhat unique, though, in the NASH field. It's the composite of both NASH resolution and fibrosis improvement of one stage and more in the same patient. And we think that, that reflects some of that unique biology Andrew was sort of hinting at and that we -- the ability of the drug to get both intrahepatic and extrahepatic drivers of NASH showed in NATiV2 that we can, in the same patient, resolve all of the features of NASH. And therefore, we brought that forward as our primary endpoint in Phase III.

And how should we think about the powering of the study?

Well powered. For a Phase III study, we are -- we've been guiding that we are powered to above 90% on the primary end, the co-primary endpoint of NASH resolution and fibrosis improvement. What we are not giving too much specifics about is what's the effect size, [ Jason ]. But what we can say is that we took a more conservative approach than NATiV2. Our effect size was 24% there with a placebo response rate of about 7%.

What we did was we took a higher placebo response rate and therefore, a lower treatment effect and powered to that. And then we overenrolled the trial slightly, and we built in -- because it's an 18-month trial, and it was getting going during COVID, so we were a little nervous. We built in a much larger sort of dropout rate than would otherwise be expected in a Phase III up to 30% dropouts, and we would still maintain and preserve that power.

Okay. So in my view, and jump in if I'm wrong, that sounds like quite conservative powering where if you're 90% powered to show what the 18% placebo-adjusted effect size in Phase II, you probably could show meaningfully lower than that and still be statistically significant. Fair?

Fair. Yes.

Another way to say that is in 247 patients, we hit statistical significance on all 3 NASH endpoints. And now we have a 1,007 patient double-blind, randomized controlled trial, we are very well powered.

And at a much longer time point where you should see increasing effects over time.

Exactly right.

And how should we think about that? How much that could...

I think broadly speaking, I mean, we don't know. In the end, it makes -- there's a rational argument made that longer treatment is going to result in deeper effect. I think the 3 lines of evidence that support that are pretty straightforward. Other sponsors have shown it. Akero has shown it, for example, when they went from 6 months out to longer. Intercept showed it back in the day when they revealed top line data on fibrosis improvement. 18 months later, they continue to follow those patients, and they had deepening of the fibrosis effect by TE. So that's very good.

And lastly, the biology of lanifibranor, the way that PPAR agonists work, the sort of metabolic reprogrammers that work at the level of DNA transcriptional activation, that just takes time. So 6 months, no doubt, we saw an effect. We're very confident in that, but it's really early for gene regulation and transcriptional activation to show themselves fully. So if all those 3 things line up, we think it's reasonable to think we're going to get a deeper effect.

How do you expect the patient baselines to compare in Phase II versus Phase III?

Yes. I'll start, it's largely similar. The big difference is we enroll more patients in the U.S. Therefore, there's more diabetes patients in the U.S. So we have 55% diabetes patients in the trial, 42% were in Phase II. And actually, the stage of disease, F3 travels with diabetes. The more metabolically dysfunctional patient, the more likely they are to have later-stage disease. And you see that with the baseline of a higher baseline of F3 patients in the trial.

The other difference in the trial was that GLP-1s really weren't around during the Phase II. We had 14% of patients that started on a baseline GLP-1, not the [ MASH ] dose, the low dose for diabetes. Those came in on a stable dose. We had another about 10% of patients that dropped in during the trial, but should be balanced by arm across placebo and drug. Anything else?

Great. That's helpful. Sorry for jumping into the trial design questions. You can tell where we're getting a lot of questions. But maybe taking a step back, my favorite topic, [ MASH ]. How do you see the landscape? There's a lot of drugs in development. You have Rezdiffra, you have GLP-1s now available. And then, of course, FGF21 is coming along. Where does lanifibranor fit in the development landscape?

Yes, absolutely. So just to take a step back first, broadly, we're at the very beginning of this market, right? We've just had 2 approvals recently, more that are going to be coming. We are in the very beginning of what will eventually be multiple classes of drug and multiple drugs in those class and growing quite substantially as a market. Where we are today is we think there's about 375,000 patients in that F2, F3 space where lanifibranor will compete. In that space, we believe there's going to be a baseline use of GLP-1s. GLP-1s for us are friend, not foe. And then physicians will layer on an oral to address the fibrosis on top of that, either Rezdiffra or lanifibranor. I'll get back to that in a second and how we see that playing out.

But just to comment on the FGF21s, we really view those as staying in F4 for a number of reasons. First of all, we believe the pharmaceutical companies will premium price those. And there injectables competing in an oral market. They've got some toxicities, both bone density and GI that are going to really prevent them from moving into that F3 market. So we're really seeing the staying in the F4 market. So bring us back to the F2, F3 market.

So how does the physician choose between lanifibranor and Rezdiffra? So the way we segment this 375,000 patients is into 4 boxes, right? It's a 2 x 2 grid. You think about F2 and F3 and they're roughly equal, 50% in each. And you can think about nondiabetic diabetic, and it's about 40% nondiabetic, 60% diabetic. So you end up with 4 equally sized boxes relatively equal, a little bit bigger for the diabetic. And where -- what's the natural habitat with these drugs? Well, if you think about an F3 diabetic patient, right, physician, let's say, lanifibranor has just launched and a patient walks in and the doctor needs to make a decision about what world to put that patient.

Let's say we duplicate our Phase II and say, okay, well, super worried about fibrosis because I don't want that patient to go to F4. I want to pick up the biggest hammer I have on fibrosis, and that's going to be lanifibranor, 18% versus 12% if we duplicate the Phase II. And if patients got diabetes, I know that's driving the disease. The metabolic function is driving this disease, and I need to address that, but probably already on diabetic medications, but why not add something that can reduce HbA1c even further. So lanifibranor becomes a very natural choice there. A patient walks in the day after lanifibranor launches, and there's an F2 nondiabetic patient.

Well, that's probably a patient I'm still going to put on Rezdiffra for now, right? It's a proven drug, it's comfortable with it, doesn't have diabetes. I'm not worried about the fibrosis going to F4 overnight. I'll stick with it there. And then you can see that as the physician gains experience that a very natural place for lanifibranor to go is then to the other F3 patients without diabetes or to the diabetes patients with F2, and that's how we see the market evolving over time. And if we end up getting better F2 than 18%, maybe we double what Rezdiffra has, then I think that you migrate into that whole market.

Yes. And that 18% was at 24 weeks now, not...

That's correct. Yes. It was 18% after 6 months versus 12% after 12 months.

Great. And so -- and then in Phase III, you're looking at 18 months?

Yes, correct. And we do expect a deepening of effect and hopefully some better results.

How do you think about the breakdown between the different prescribers, especially given this effect that you're seeing in diabetic patients as well as maybe more physician familiarity from endocrinologists with the PPAR class. As you think about the segmentation, I mean, it seems like -- right now, most of the NASH patients that are being treated are being treated by hep, GIs, less so in the endocrinology segment. Where do you see this evolving in the coming years? Because I mean, correct me if I'm wrong, but I would guess that a lot of NASH patients are sitting with endocrinologists right now.

Certainly, the endocrinologist is probably keeping them in the opinion of the GI and the hepatologists probably keeping them too long. So -- and this is something we will make a decision now about how we do this. We'll definitely be monitoring it. But overall, you can think of -- we clear that we're not going to be looking to get switches in terms of patients off of Rezdiffra, on lanifibranor. We're looking for new patients. So we'll monitor closely kind of how the market is growing, where the diagnosis is happening and where those new Rxs are. I think GIs and heps are clearly going to be a call point and a starting call point for us. And whether we add endocrinologists at the time of launch remains to be seen or to what scale. But I think certainly, there's at least a subset of endocrinologists that should be in the targeting and launch.

And what proportion of patients do you expect in your Phase III to be on GLP-1s at baseline?

So baseline GLP-1 use in NATiV3 is a little less than 15%. So they needed to be stable treatment, non-NASH dosing. So you're talking, one, it's not all sema. I think all eyes and heat and light are on sema, but it's not only sema, there's liraglutide, dulaglutide as well. But whatever it is, they need to be on stable dosing and it needs to be the diabetes dose because it's for concomitant comorbidities, diabetes in this case and not for NASH.

So we like that data set across both. We have 2 cohorts, the main 1,000 patient randomized double-blind and then a sort of expansion cohort for screen fails of about 400 patients. That would give us a data set of about 300 patients. And I think as Andrew mentioned earlier, GLP-1s are going to be the backbone of the therapy, particularly patients entering at that F1, F2 side. Ones that are caught later by the heps, GIs, not clear that they'll be on GLP-1s, but clearly, the earlier ones will be. The idea that we'll be able to have data that say that we work and play well with GLP-1s will be fantastic. So we think it's going to be a good data set.

And then the mix of F2, F3 patients in your trial that you expect?

It's contemporary. So we have roughly 2/3, 1/3, 2/3 F3, 1/3 F2, which is fairly similar to what [ Madrigal ] had in their Phase III program. It's a little different than our Phase II, but the world has changed. As Andrew said, we have more diabetics today that both have NASH. So that's also reflected in the diabetes status. We have about 55% diabetics in the NATiV3 trial compared to about 45% in NATiV2. So both of those really reflect the contemporary practice today.

And that's helpful because you're enriching for the patients that were better responders in Phase II.

Well, it's interesting. We actually did a responder analysis. We published it after the NEJM article in 2024. Independent of diabetes status, the drug actually works equally well. So even if you strip out the F1s from NATiV2, the drug works slightly better in F2, F3, but I'll say here that it works equally well. So one, we're not getting a free ride on the back of the sort of lesser severity patients. And second, diabetes isn't giving us the kind of tailwind.

But on the other hand, in the presence of diabetes, or hemoglobin A1c reductions like in our LEGEND study approach one full point. So that has all the makings of a drug that could be valuable to endocrinologists as they're trying to manage both diseases. So although it doesn't work better on histology, it does have the glycemic effects in the diabetics.

Right. Makes sense. That's helpful. A question that we get from investors a lot is around safety, particularly the history that the PPAR classes have with safety. Can you walk us through the history of the safety of the PPAR class briefly? I know there's a lot to go through on the PPARs, but just kind of an overview of that and where you see lanifibranor falling and your confidence in the safety.

I'm going to hand that one to you.

That's so kind I'll actually pick up where Andrew left off. So lanifibranor was rationally designed by a group of chemists that were PPAR biology founders. They had created fenofibrate back in the day. And their goal was to sort of get the biology that these metabolic reprogrammers, PPARs could do without a lot of the baggage of some of the therapeutics that have been on the market. So the stepwise approach was design the molecule. Second, run the toxicology data in conjunction with FDA to say what's true for this drug and what's not true.

And back in 2019, we had publicly talked about that, that toxicology program Andrew mentioned, full 2 years to 2-year rodent 1-year nonhuman primate, discharge many of the traditional PPAR risk, things like cancer, muscle damage, kidney damage sort of went away. And that it showed that as predicted from the structure of the drug, we had gamma effects, but they looked a little muted and blunted compared to like pioglitazone or rosiglitazone. So very good. Rubber meets the road in clinical trials. And what we showed in NATiV2 sort of confirmed all of that.

So if you look at an adverse event table in NATiV2, it looks like a lanifibranor adverse event table. It doesn't look like other PPARs. It's its own footprint. What's absent are a lot of the PPAR alpha delta safety issues, good. But what is present are some of the gamma concerns, but they do appear to be muted compared to what you see with longer-term bigger studies with pioglitazone. We do have weight gain, for example, but it appears to be less than what you would see in pioglitazone, and it tends to plateau after about 6 months or so, good. The peripheral edema that one sees associated with that weight gain appears to be less.

And the final arbiter of that is the congestive heart failure signal. Now obviously, we're running a blinded clinical trial, but based on NATiV2, we like that step off a lot, less weight gain, less edema and much, much less heart failure compared to sort of historic norms. So I think in summary, we like our safety profile, not because it's better than pioglitazone, it's our own. And it's been sort of matched with exactly what the people that designed the drug 15 years ago were hoping that they would get in the clinical environment. Stripped of a lot of the safety baggage, but still getting you the same intrahepatic and extrahepatic biology that made PPAR so interesting in the first place.

What are you seeing in terms of weight gain? And how does that compare to what's seen with pioglitazone?

So why don't you start with the weight gain and then I'll go to pio.

So I think -- the first thing to understand is about 50% of patients in our Phase II did not gain weight. 20% gained very modest 2.5% to 5%. And there was a 30% they gained 5% or more. What's interesting is the way the doctors code that, right? If you look at the adverse event table, a weight gain is only 10% because in many -- this is not perceived as an adverse event. It's really a tolerability issue and physicians actually only recorded 1 out of every 3 patients with that weight gain over 5%. So that's the facts of where it is. Maybe I can hand it to you to talk about kind of what the biology is, and then I can talk about how we think this will play in the market.

Yes. So on the one hand, the gamma effect of pioglitazone and rosiglitazone, these are incredibly strong metabolic reprogrammers. In fact, pioglitazone probably has some of the best glycemic data that exists ever. I mean they're fantastic. They even had outcomes back in the day. It was in the 1990s. I don't think people think about outcomes in that regard. But they actually had really good outcomes in diabetics that had macrovascular disease when they looked at like what we would think of as sort of a MACE endpoint today. Hazard ratios look pretty similar to what we've seen in the monitor. The problem was that it came along with this question of weight gain edema and congestive heart failure.

So what we see is, generally speaking, the weight gain that looks -- it's about proportionately numerically less than what you might see with pioglitazone. More patients tended to gain more weight with pioglitazone and it lasted a longer time. So if you follow those patients for years like in the PIVENS study, the weight gain kept going up and up and up, and it reached a plateau maybe at year 3 as opposed to something like maybe month 6 or 9, which is where we're landing. And the overall magnitude of the weight gain, which is what Andrew just showed is less.

And when you step that down, the peripheral edema, in some cases, looks to be fivefold lower than what we reported in some trials. But if you look at the label, for example, it might be two to threefold lower than what was reported. So we like that. We call it a sort of blunted or attenuated gamma effect, but it still is very clearly a gamma effect, which is really just salt and water retention in the end. So that's what all this comes back to is that the gamma works by modulating salt reabsorption and you get some peripheral edema and fluid retention.

But then I think just to bring it back to that market segmentation that I talked about, that it is so a chance of weight gain is going to be part of the profile. For that F3 diabetic patient population, that is a perfectly acceptable part of the profile in terms of physician choice. For the F2 nondiabetic, that's probably where it becomes a little bit more of a liability unless your fibrosis score is so good that it overcomes that, right? So it just plays into that market dynamic.

We've seen in labels across the PPARs, black box warning for congestive heart failure associated with the edema in warnings for bladder cancer risk. As we think about your profile, what are the reasons why you think you're seeing a lower risk relative to pioglitazone?

So it's a tricky question, right? Because in the end, FDA gets a big vote, too. So -- and we don't have full data yet from NATiV3. So it's all highly speculative. But that being said, the 3 elements that matter are what's your drug, your class, what are your data? And can you manage the risk in a trial environment or market environment? Number one, we have a different scaffold. We are not a TZD. We're a completely novel agent. So we're not pio that also happens to have alpha and delta. We are a completely novel agent there.

Second, we'll have our own data sets, as we just talked about, they will or they will not look differently in the end than pioglitazone that will matter. And lastly, how are we doing in the clinical trial when the FDA ultimately looks at were you able to manage whatever effects you see. If they're comfortable that it's a different drug and the data look different and you're managing risk well, well, then there's no reason for a box warning.

That being said, FDA has decisions of their own, and they may still say, you're going to get a box no matter what. But we actually think we're in a really good position to walk in with a straight face argument, not the same drug. We have our own data set. And we think we've done a really nice job in a trial environment of managing our risk. Therefore, this is the label that we're proposing based on our data. We'll see what we get.

That's helpful. And what are your plans in F4?

I'm sorry.

Your plans in F4?

Do you want to start?

Yes. So we are -- we will be approved under conditional approval in the U.S. for F2 and F3. So we'd have to do an outcomes trial. We are choosing to do that outcomes trial in F4. I'm willing to find that a little bit more. So we'll start that trial after we get data. We have to have substantially started by the time we file our NDA. But we're looking to choose a patient population that is sick enough that it can progress to outcomes, we can measure outcomes, but not so that we can't reverse the disease. And we've identified a patient subgroup that has portal hypertension that we believe is the right target for that trial. I'll hand that over to you to maybe to explain the biology.

Yes. I mean this is -- honestly, this is a really active area for those that are listening. It just -- it will develop over the next couple of years. But this idea that we can now identify easily at the bedside, a group of patients that are either advanced F3 or F4, but they have the physiology of cirrhosis, portal hypertension, as Andrew said, that you can identify them easily at the bedside really makes the possibility of putting them in clinical trials really attractive. So this idea that you can have a group of patients in the trial that have the portal hypertension that puts them at much higher risk of liver-related outcomes, that's fantastic when you think about a trial design perspective.

But what we like the most about it is that, that group of patients appears to match the biology of lanifibranor really nicely. The intrahepatic and extrahepatic modifying elements of lani on the alpha, delta and gamma PPAR receptors, each of those pathways are driving some of that portal hypertension. So we have a fair bit of preclinical data that we published over the years, including at the liver meeting last year, AASLD in Washington sort of outlining that data. So we're excited. And we have about 75 patients roughly in our expansion cohort in our Phase III program that was a really nice view of the safety of both doses of lanifibranor. So we're excited to begin to talk to FDA about this and build that trial.

Strategically, we've seen 3 acquisitions in the [ MASH ] space in the last year. You are a fraction of [ Madrigal's ] market cap. Those are just fast. I'm not speculating. How are you thinking strategically about your plans for commercialization and what might make the most sense, whether you go it alone or seek a partner?

Well, [ Madrigal ] has really laid out the path for how a midsized biotech can commercialize successfully and drive to profitability. So we plan to follow that path. So you should expect us to -- if we have positive data to raise a lot of money to be commercializing ourselves. Now along the way, yes, you're right, there might be some strategic interest that might prevent us from realizing that mission. But we are planning to commercialize ourselves in the U.S. definitely and then secondarily in Europe.

What is your cash balance and cash runway currently?

So cash runway goes to about Q3 '27 right now, so well on the other side of data, which gives us a lot of room to make some strategic decisions post data.

Great. Just a question on the confirmatory study. How are you thinking about how you might design that and start it shortly before we might get the data for [ Madrigal ]? I can imagine that's not...

Not exactly. I think what FDA wants is very clear on this. You need to have the trial meaningfully underway at the time of approval, at the time of filing that the trial started. And then prior to that, we have a lot of opportunity to engage with FDA on exactly how they define that. That's the point of it. So it's not a get going and let us know how you're doing. It's active engagement with them at the prefiling meeting, the interim mid-cycle review meeting. But our plan is that clearly, we will wait for data to have any meaningful start on that study, but we're already laying the groundwork for that now.

Great. Awesome. Well, I think we're out of time, but I appreciate both of you joining us today and certainly an exciting year ahead, ahead of the Phase III data.

Thank you. Thanks for having us.

Thank you.

Welcome, ladies and gentlemen. Welcome to the last day of JPMorgan Healthcare Conference and today's presentation from Inventiva. It's my pleasure to introduce Andrew Obenshain, CEO of Inventiva. We'll first do the presentation after that, there is time for some questions. So feel free to save those to the end.

And I'll leave it to Andrew to take us through.

Thank you very much, and thank you for having us at this conference, and thank you for ordering up some beautiful weather this week. I'm glad to see there's a sellout crowd of hundreds of people in the audience for those people online. A lot of interest in Inventiva today.

So again, I'm Andrew Obenshain, I'm the CEO of Inventiva. Today, I'm going to talk about the company and our lead asset, lanifibranor, which has the potential to be best in disease for MASH as an oral therapy. This is my disclaimer. This presentation contains forward-looking statements. I will not read the whole thing.

And I want to start this presentation by just talking about the company a little bit instead of the product because Inventiva has really gone through a transformation in the last 18 months. We currently have a fully enrolled Phase III trial. That Phase III trial design was based off of a Phase IIb of well over 200 patients that was published in the New England Journal of Medicine with positive results and the design of the Phase III is largely similar, and we anticipate that readout in the second half of this year.

The company itself has received a substantial amount of funding over the last 18 months, starting with a $411 million raise in October of '24 and supplemented with $172 million in October. That's important because the history of Inventiva has been one of scraping together a couple of pennies to get to the next stage, and now we're actually fully capitalized to realize the full potential of lanifibranor.

Along with the first fund raise, Mark Pruzanski, the former CEO of Intercept, joined as the Board Chairman, bringing a lot of expertise in MASH. And he has proceeded to build up the management team, starting with addressing the medical and regulatory side. We brought in Jason Campagna, who is the former CMO of Intercept; and Martine Zimmermann, the former Head of Regulatory at Ipsen, where she got the PPAR approved. So very relevant experience to really shepherd lanifibranor through.

We've added commercial expertise with Nazira Amra from Intercept. And then I've joined -- my background is as a public company CEO, transitioning biotech companies from Phase III to commercial. So we now have a well-funded company, an experienced management team, a fantastic asset to bring forward into a very exciting MASH space.

So I'm going to start by just talking a little bit about MASH and what we think is needed to address the unmet need of these patients. So MASH is a chronic progressive disease. It's the #1 cause of liver-related death, but it's more than just liver disease. It's more than just liver scarring. It is a cardiometabolic disease. It's really part of the cardiometabolic metabolism. These patients have both a sick liver with scarring, but also a sick body. Over 60% of them have diabetes, obesity involved. And really to address the liver issues, you need to address both the sick liver and the sick body. We believe that lanifibranor is a product that is positioned to do just that.

In terms of the market, this is a market that's going to grow to $15 billion by 2035, but it's not there yet. It remains a market of a lot of opportunity. There's about 2 million diagnosed MASH patients in the U.S. right now, just under. That's only about 10% of the total population. But that diagnosis rate is increasing very, very quickly. Our current estimate of 2 million diagnosed is -- represents a growth of about 25% since 2024.

And the patient population that we'll target is the F2, F3 patient population. That's about 375,000 patients in the U.S. that are under care of a physician. And again, that represents growth of about 20% since 2024. But that patient population has been -- the patient population that's been sufficient to drive the first oral to the market to a run rate of over $1 billion in sales. So this is a market that is growing and a lot of opportunity.

Now one of the reasons the market is growing is because there's been a lot of activity and positive activity. There's been 2 approvals in this market recently, one GLP-1 and one THR beta. And that has increased the diagnosis rate and the awareness. But it also presents a question of where does lanifibranor fit in. And so the way we see the treatment of MASH evolving is that any patient that is F1, F2 or F3 will have tried, will soon try or will be on a GLP-1. That will be the backbone of therapy for these patients because GLP-1s really address the underlying metabolic issues.

There's also FGF21s. We view that those therapies are very promising therapies, but really will remain in F4 because they're injectable, they have some overlapping toxicities with GLP-1s. They're probably -- and this is speculation, going to be premium priced. So they really will stay in that F4 patient -- and we see the future as for F2 and F3 patients as a GLP-1 plus or minus an oral, and that oral will either be Rezdiffra or lanifibranor.

So let me go into lanifibranor and specifically how it was designed and the mechanism of action. So lanifibranor is a pan-PPAR agonist. It was rationally designed based on over a decade of PPAR biology and understanding. It was not made on the old TZD backbones, rather it's a new chemical entity, so it has its own properties. And really was designed with 2 goals in mind. First of all, to be a low potency binder across all 3 isoforms.

Now why is low potency? Why? We usually in drug development, we like high potency, we like tight binders. But it's been shown that especially for the gamma isoform, if it binds tightly and have a high potency binder, it leads to adverse events that we want to avoid, for example, peripheral edema. And this was the case with rosaglitazone, which was a tight gamma binder that was withdrawn from the market in Europe.

We also want to be balanced across all the isoforms. We want to recruit not only the liver effects, but the body effects and also the balance actually helps to -- these are networked receptors and hitting them all together leads to a much more balanced profile and safe profile. So -- and one of the reasons we want to be balanced across all 3 isoforms was we want to recruit both the liver effects and each isoform has different impacts on the body.

So we want to address steatosis, PPAR gamma, fibrosis, PPAR gamma and alpha, inflammation and ballooning, PPAR -- all the 3 PPARs and vascular gamma and delta. And then we also -- for MASH, especially want to address the metabolism. And a pan-PPAR addresses insulin sensitivity, it lowers HbA1c, increases HDL and lowers triglycerides. So that was the goal of the design of lanifibranor.

So let's turn to the clinical data. How this was the goal of design, how did the drug actually perform in patients? Well, in the Phase IIb study, which these were published in the New England Journal of Medicine, with only 6 months of treatment, so 24 weeks, lanifibranor improved fibrosis and key metabolic markers. So we saw an 18% effect size on fibrosis. And if we looked at both fibrosis and mass resolution, that actually grew to 24%. In addition to that, it improved the cardiometabolic glycemic and metabolic markers. So it did -- it delivered as promised in the clinic.

Now that Phase II trial was, again, 6 weeks, and it was 2 doses, 800 and 1,200. It included F1, F2 and F3 patients, and the primary endpoint was an SAF score, so a steatosis activity fibrosis score as measured. This is not what -- our Phase III is going to look very similar to this, but not quite identical. So I'm going to go through a couple of differences and maybe what impact those will have.

So let's start, let's reground ourselves in the efficacy. So on the dual endpoint, the resolution of MASH and improvement in fibrosis, that is what's going to be our primary endpoint, not the SAF score. And that is where we had that 24% effect size in the Phase II. Now our Phase III is going to include no F1 patients. It's just F2 or does include no F1 patients, just F2 and F3. So how do we do an effect size in that population? Well, roughly the same, slightly better. So we're confident that the elimination of the F1 patient population from the Phase III is actually -- has either no or positive impact.

Also, we're running the study or the study was run more in the U.S. than the Phase II, and therefore, there was more type 2 diabetes. So the patient population is slightly enriched for type 2 diabetes. And again, you see that the effect size remains similar, actually slightly better. So we're -- that Phase III patient population is -- we're confident that we can duplicate that Phase II data.

Now these are the histological findings from the study, but the biomarkers also support the same efficacy that we saw. So we saw a statistically significant decrease in liver enzymes, ALT, AST, gamma GT, and this was rapid and sustained improvement. And we also saw a number of extrahepatic benefits, including the lipid profile improving with HDL going up, triglycerides going down. There was no change in LDL. There was significant reduction in HbA1c. In fact, it went down by half -- just over 0.5 point that would have been an approval diabetes product back in the day. We saw significant improvements in hepatic and muscular insulin sensitivity. We saw a decrease in diastolic blood pressure that was not statistically significant, but something we'll be measuring. And we saw increases in adiponectin levels as well up to threefold and over threefold at the higher dose.

Now that's how we did on efficacy, which was quite compelling and really led the company to start that Phase III. And on safety, how did the rational design impact the safety of the molecule. So overall, what the concern about PPARs is peripheral edema. And if you look at the peripheral edema rates and drug-related peripheral edema rates in our Phase II, it was just at 2%. So it appears that the design seems to have mitigated some of the worst impacts of the gamma of PPARs.

We did also have weight gain in the study as has been reported with other PPAR agonists. That weight gain appears to have been milder than previous PPAR agonist. Half of patients gained no weight, so there was no impact. 20% gained less than 5% and 30% gained 5% or more. And this profile, remember the profile of really robust fibrosis efficacy, cardiometabolic benefits, we think -- when we talk to physicians, we think this is a very competitive profile in the MASH market.

So let me move to the Phase III. Again, this is a fully recruited trial. The last patient was enrolled in April of last year. The -- as opposed to being a 6-month trial, it is an 18-month trial. So a full extra year of follow-up, and we do hope for a deepening of effect over that extra 1 year. The main cohort has over 1,000 patients enrolled, so a very large trial, again, 2 doses. And the key differences between the Phase II and the Phase III are, as I mentioned, the type 2 diabetes, again, no F1s. And there are a number of patients, 14% that actually started the trial on a baseline of GLP-1, a steady dose of -- or a stabilized dose of GLP-1 as opposed to we had no patients in the Phase II as GLP-1s were really not used that much at that time.

So importantly, from this as well, we have an exploratory cohort where any screen fails, F1 or F4 go into an exploratory cohort. So we will have a population of F4s coming out of this, where we should have some data. And that is particularly important because the next step for Inventiva is an outcomes trial. So because we are using a histological endpoint, which is used as a surrogate endpoint by the FDA and the EMA, we do need to do a confirmatory trial. And we are going to start an outcome study in patients with compensated cirrhosis, MASH to confirm the clinical benefits. We have to measure either the prevention of progression to cirrhosis or a reduction in associated clinical outcomes, such as decompensation, cancer or liver transplant.

So we're actively designing that trial now. And some early thoughts on it are that we need to have a patient population that is sick enough so they can progress to get events, but not so sick that we cannot reverse the pathology of it, right? So there's got to be this Goldilocks patient population that we can study. Otherwise, we're doing a 10-year outcomes trial, which no one wants. And we do believe that there is a patient population of compensated advanced chronic liver disease or cACLD that meets that criteria. These are patients that have advanced fibrosis or cirrhosis, but no outward signs of liver disease. However, you can identify them through noninvasive tests.

And one of the key hallmarks is they have portal hypertension. In other words, the blood flowing into the liver is not flowing out as quickly. It's backing up into the circulation system of the body and leading to varices in the esophagus and other places. And importantly, preclinical data suggests that lanifibranor can address the etiology of that cACLD patient, that portal hypertension. So we'll be exploring this more and giving more details on this as we go through the year.

All right. So what can you expect from Inventiva in the next 24 months? Well, we will report out data this year. We will start our F4 outcomes trial at the beginning of next year sometime and then file with the FDA as well and the EMA. And we anticipate a potential market launch for lanifibranor in 2028. And we do so from a position of strength. We have a cash balance that runs us out to Q3 '27, and that assumes the third -- positive data and the third tranche from the PIPE that we did in October '24 coming in and funding the company. Just as a reminder, we own this asset fully with the exception of out-licensed in China, Japan and South Korea with a very low royalty burden. So this is a fully owned asset by Inventiva.

So to summarize, we have a wonderful -- asset that has -- a therapy that has the potential to have real clinical benefit in a very large unmet need patient population with a large potential. We have a company that is well funded with a really strong management team, and we're looking forward to giving you updates throughout the course of the year and having a very successful 2026.

And with that, I will hand it over to you, to our questions in the audience. Thank you.

Any questions from the audience here? Otherwise, I would like to kick it off. I mean, I sat here a year ago, it's great to see the progress since you started the job in October. Any first impressions? And how has it been going?

It's been -- so I would say that there is a -- this is a French innovation company that has done a wonderful job of progressing this asset as far as it has. I think it was a real pleasure and surprise to come in and just see how well this trial had been executed and just the potential impact on patients that it has this is in terms of actually reversing stages of fibrosis. I did not, as first time in the MASH market, appreciate just the damage that liver disease does to these patients and the impact that you can have by reversing it. So very impressed with what the company has done so far.

Great. And with the recent management changes, is Inventiva planning to becoming a U.S. company?

No, we're going to stay France based. While we build up our U.S. commercial infrastructure in the future, but we will be -- I think we'll move from a French innovation company to a transatlantic international company that's still based in France.

Great. That's -- pleased to hear. I see we've got one question from the webcast, which is, is there any -- I mean, you commented on the planned filing of the data. Do you see any risk factors, limiting factors that could result in a later filing?

So we are -- I always say that we're not Pfizer, we're not going to file it is in 1 day with a COVID vaccine. No, but we have -- I think right now, we are building up such a very strong team that has experience prosecuting these types of trials, collecting the data, cleaning the data, moving from last patient, last visit to top line data, moving from top line data to NDA filing. So I think we're going to move very efficiently going forward.

And what's the company currently doing to prepare for commercialization?

Yes. So this 2026 is a year of strategic preparation, doing a lot of market research, preparing some market access, thinking strategically about which geographies we want to be in at what point, probably building up a little bit of presence in medical affairs for 2026, really with the preparation to scale robustly in 2027 after data.

Good. Any further questions from the room? I think we leave it there. Thank you.

Yes. Well, thank you, everyone, for coming today. Don't jostle on the way out. And we will -- we look forward to giving updates through the course of the year. Thank you.

Thank you.

Okay. Why don't we kick things off. Hi, everyone. I'm Mark Pruzanski, I'm the Chairman of the Board of Inventiva and welcome to our investor event. We're going to be telling you today about the next and hopefully best-in-category oral therapy to get to patients with MASH, lanifibranor. We're going to be making forward-looking statements. Here's the agenda.

It's going to be pretty packed, and I'm going to get out of your way and introduce you to Andrew in a minute followed by 3 well-known, key opinion-leading hepatologists in the MASH space. And then we will a panel discussion with some of the senior management team and time for Q&A at the end. So I've been involved with Inventiva for the better part of the year. And it's been a momentous year. All of you know that we just about a year ago raised a $400-plus million pipe, which positioned the company very well with respect to the enrollment of the global Phase III NATiV3 trial.

We double-clicked to accelerate enrollment and over enrolled the study, which we announced in April of this year. And then in the last few months, we've been working hard to strengthen the management team. So over the summer, we announced the addition of Jason Campagna, many of you know him. He worked with me at Intercept as our Chief Medical Officer there, knows the space extremely well. And we are very pleased to welcome him as the CMO and President of R&D; and also Martine Zimmermann, who is here, who is a longtime Board member at Inventiva and most recently was Head of Global Regulatory Affairs at Ipsen, where she helped to shepherd 2 liver drugs, including elafibranor PPAR agonist for the treatment of PBC. So she knows the liver disease space very, very well and FDA, the liver review division and other regulatory authorities, of course.

And then just a week ago, we were thrilled to introduce our new CEO, Andrew Obenshain, who many of you know, most recently, he was the CEO at bluebird. He has extensive global biopharma experience, number of leadership positions, especially in the commercial side. So he'll be leading the company going forward as we set the stage to bring lanifibranor to market. Andrew?

Thank you, Mark. Welcome to everyone in the room. Welcome to everyone online to or listening to the recording later on. As Mark said, I'm Andrew Obenshain. I've been with Inventiva for a total of 6 days. So there's probably people in the room that know NASH or MASH even better than I do, but I have 6 days of knowledge that I would like to share with you.

The first thing I want to do is thank the team at Inventiva for the work over the last 12 years since I come in as a new CEO inheriting a fantastic platform for the future. We've enrolled -- fully enrolled a Phase III trial as of April. That Phase III trial was designed on positive data from the Phase IIb that had some -- set the standard for, I would say, for efficacy in oral in the MASH space. And we have an asset in lanifibranor that really has a potential to make a difference for patients in a really large and growing market in MASH.

So I couldn't be more excited to take over at this point to take Inventiva from a commercial -- sorry, from a development stage company into a commercial stage company, which is something I've done before, been through a number of launches, and I'm really excited to do it here as well.

So I'd like maybe to start off, what I'm going to do is, I'm going to cover a couple of topics. I'm going to give a little bit of an overview of MASH. I think many of you are familiar with that. I'm going to talk about how that MASH space is developing over time, where lanifibranor fits into it and what the future is for Inventiva. So for those -- most of you know that MASH is a very -- it's a liver disease. It is progressive. It starts off with -- it starts off with fatty liver, leads to then inflammation followed by liver damage.

It is the #1 cause of liver transplants in women in the U.S. It's #2 overall. And despite that, despite the severity of the disease, it remains incredibly underdiagnosed. So of the 18 million patients in the U.S., only 10% of those patients are diagnosed right now. And even if we go even further and say, well, how many of those are under treated care and specifically focusing on the F2 and F3 patients, which is what we're enrolling in our clinical trial, what will be the commercial target, there's 367,000 patients. It's a very precise number, 367,000 patients under treated care right now in the U.S.

Now that -- I've done a lot of launches into markets that are underdeveloped. And usually, you think it's going to do a lot of market development to actually grow that number. However, that number, that 367,000 is 70% higher than it was even 4 years ago. This market is developing already. So why is that?

Well, MASH is a subsegment of the metabolic space. And like the entire metabolic space, there has been a tremendous amount of innovation, a tremendous amount of investment in this area, MASH not excluded. And so we've had 2 new products come to market in the last couple of years in MASH, which has really prompted the development of this market as well. And there's a lot more coming. However, even with 2 products in the market, almost 9 out of 10 physicians say that there's still a need for more efficacious products and specifically products that target the liver.

And this is where lanifibranor comes in. So we believe that we have a therapy that is uniquely positioned to deliver on the physician and the patient needs. So let me actually start with the patient. This is a simple product for patients. This is an oral once-a-day therapy with manageable safety and tolerability profile. And if we look at our Phase IIb data, it's a product that works. It has potential best-in-class oral efficacy. We've showed an 18% improvement in fibrosis in just 6 months.

And that's really based on -- that efficacy is based on a unique mechanism of action in the market. This is a pan-PPAR agonist. And it was actually designed specifically for MASH. And it works on both the liver with direct fibrosis -- directly on fibrosis in the liver and also has extrahepatic benefits in cardiovascular markers as well. So we believe that we have a therapy that really can make a difference for patients in MASH.

Now what's next for Inventiva, right? So I'm standing here in front of you as a new CEO. You've just heard that we've brought on some new management recently as well. And that is to prepare for what we have some real milestones coming up in the next 2 years. So we are super focused for the next year on delivering the clinical data, the top line results in the second half of 2026 and then launching this therapy in 2028. I feel very privileged to have come into a company that has had such a wonderful asset developed. I feel privileged to be able to bring my experience in launching therapies, both in Europe and in the U.S. to Inventiva.

And I think that we have a very bright future as a company. So I'm going to get off the stage in terms of the background and actually hand you to the experts that can tell you much, much more about MASH. And I would like to hand it over next to Dr. William Alazawi, and he's going to bring us through pan-PPAR in MASH.

So yes, I'm William Alazawi. I'm Professor of Hepatology in London. And it's a real pleasure to be with you here in New York City today. And I'm very excited to talk to you about PPARs, PPAR agonists and how those mechanisms link into steatohepatitis and fibrosis. So Andrew has already touched on this, and I'm sure I don't need to tell this audience that metabolic dysfunction associated steatotic liver disease is a spectrum of disease entities that starts with the accumulation of steatosis or fat in the liver.

Now a proportion of those people will go on to develop steatohepatitis, which is the inflammatory, progressive form. When that fails to resolve, you get fibrosis or scar tissue being deposited in the liver. A little bit more fibrosis is a bit more again and patients can progress to cirrhosis, and that increases the risk of developing liver cancer or liver failure requiring transplantation. Now you only need to look at just how common this condition is amongst people living with type 2 diabetes or with obesity to really hammer home the point that this is a metabolic condition.

And at its heart, that metabolic condition is associated with liver diseases we've already seen, but also increases the risk of cardiometabolic comorbidity or mortality also. And what this graph is data that supports what we've known for a long time, which is that if you take the fingers of one hand and tot up the number of cardiometabolic risk factors the patient has got then that indicates that the patient is going to run into trouble. And if you look at what's underpinning those cardiometabolic traits, those are all closely linked to insulin resistance.

And that's a really important driver of this disease. Now we can't get away from the fact that the obesogenic diet and the effect that, that has on the gut, the obesogenic environment, the societal factors in which this disease develops, physical activity or lack thereof, all play a role. But if you ask how much of that dietary composition is actually translated into fat in the liver, it's not that much. The vast majority of the fat that we see in the liver is a direct consequence of insulin resistance. So insulin resistance in the liver means that there's too much glucose flying around. And despite that, the liver is making new glucose. It's breaking down glycogen to make even more of that glucose pool.

Also -- so that's called de novo lipogenesis, it's also driven that way. That means there's new fat being made in liver cells. In addition, over in the adipose tissue, insulin is supposed to stop fat being broken down, but a failure to respond to insulin means that there's excess fat delivery to the liver where it's stored and manifests as steatohepatitis. Meanwhile, in the pancreas, the beta cells are working super, super hard to make lots and lots of insulin, and that's a problem.

And the muscles, which should be spending energy like it's going out of fashion like wasteful teenagers, if you like, well, they're not doing what they need to be doing either. And the lipid-loaded hepatocyte is not a happy hepatocyte. It activates reactive oxygen species, or oxidative stress, activates inflammatory pathways that leads to liver cell damage, infiltration of inflammatory cells, activation of resident inflammatory cells and this cascade eventually leads to the activation of stellate cells that lay down fibrosis and start issue in the liver.

And this orchestra of tissues and of cells within the liver that are driving the disease are coordinated or conducted by nuclear receptors. And prominent amongst those nuclear receptors are the PPAR family. And those PPARs affect lots of different roles. So if you start with the PPAR alpha isoform, this is the one that's most expressed in the liver. This is the PPAR that as the liver disease progresses, you get less and less amounts of it expressed anyway. So steatohepatitis and fibrosis are both associated with low levels of this.

PPAR alpha maintains healthy carbohydrate and fat metabolism, turns on fatty acid oxidation, the burning of fat out of the liver cells. It also has effect in the adipose tissue as well where it's doing the same sort of thing. The B2 delta subunit has got lots of effects across fatty acid oxidation, but really excitingly has an anti-inflammatory effect on those infiltrating immune cells and also suppresses the fibrosis producing cells.

And finally, PPAR gamma, and this is the isoform that's also involved in maintaining healthy adipose function. So fat tissue biology is maintained by PPAR gamma. It also insulin sensitizes, so it reverses some of that insulin resistance that we've got. And that adipose biology is really important because there's a redistribution of weight from the unhealthy visceral adipose issue through to the subcutaneous adipose tissue, perhaps speaking a little bit to the weight queries that have been raised.

But we've known about PPARs for a long time, and we've known that they are really critical in metabolic diseases. And in the early 2010s, we had the PIVENS study and Professor Sanyal, who's going to follow me, was the lead author on that New England Journal Paper, and that proved the concept that modulation of this class of nuclear receptors could affect steatohepatitis. And there was significant improvement in steatohepatitis. And despite the fact that there was no effect on fibrosis, the drug was prominent and recommended in various guidelines around the world. But the field didn't stop there.

There was work around the receptor, understanding more around that, understanding more about developing drugs that could activate those receptors, such that now already in routine clinical practice, we've got PPAR agonist being used for liver disease. And that brings us to lanifibranor, which is a, as we've heard already from Andrew, is a pan-PPAR agonist. And it's different. It's not a glitazone. So it is a small molecule, which means it could take it orally. It doesn't need to be injected. It induces different co-factors and it can be taken once a day, and there are 2 different doses being worked out at the moment.

And the graph on the left is in pharmacology that just demonstrates that it is acting across all 3 of those PPAR subunits. So that's concept. That's mechanism and sort of theorizing as to what may be going on. But actually, when you give the drug in here is an experimental medicine setting, so this is a very carefully constructed study, where a small number of people were given either lanifibranor or placebo and then fairly sophisticated metabolic parameters were assessed.

You can see over there on the left-hand side in the graphical abstract the lanifibranor led to reduction in intrahepatic triglycerides, reduced insulin resistance, adipose tissue, insulin resistance went down as well and the muscles also responded. And I'll draw your attention to this adiponectin increase by twofold. We'll come back to that in a moment. In the native, the Phase IIb trial that we've just heard about, we're going to hear more about in more detail in a moment, there was a reduction in fasting glucose, reduction in triglycerides and an increase in the good cholesterol, HDL cholesterol. All speaking to a wider metabolic benefit in addition to the headline liver results that we see.

And when we think about inflammation, systemic inflammation, ferritin going down, highly sensitive CRP, all of relevance to cardiometabolic diseases improving and adiponectin going up as well. Adiponectin is an adipokine. That means it is made by adipose tissue, and it's involved in insulin resistance and sensitization, but it's also anti-inflammatory. And I think that makes for a very fascinating readout. But the other thing to consider, and I'm sure you are all aware of this, is that this is not happening in a vacuum. So patients when they arrive with a diagnosis or be it they may be underdiagnosed when they arrive with that diagnosis may already be on medicines for their cardiometabolic comorbidities.

So GLP-1 incretin use or SGLT2s. And the evidence base for these medicines is broad across that metabolic spectrum. But with respect to response in terms of liver disease, the doses that they may be on may differ, adherence may differ and reimbursement issues, certainly where I work, I work in the United Kingdom, access to these medicines is not as widespread as one would expect based on their indication profile. Updated guidance for example, in type 2 diabetes would suggest that these drugs should be used earlier.

And in fact, you might almost call them sort of first and a half line after metformin, if you really read between the lines of the ADA guidance. So that means that patients with MASH may be on drugs that have an effect at diagnosis. And so when we think about what a drug might do -- what drug we might use, we need to think about how we partner with them. So could I imagine a synergy between, let's say, a pan-PPAR like lanifibranor and the GLP-1 backbone, the answer is probably yes, because that synergy would look good in terms of improvement in HbA1c, insulin sensitization and lipid profile.

You've got the weight loss independent effects of the PPAR together with the weight loss mediated benefit of the GLP-1, and you've got improved dyslipidemia and triglyceride levels, which has got a cardiovascular benefit as well. And I've mentioned the adiponectin. So in summary, what I think I've shown you is that lanifibranor through its mechanism of action, acting across all the PPARs improves insulin sensitivity. And I hope I've made the link between improving insulin sensitivity the mechanisms of disease and what outcomes we want in our patients.

So thank you very much indeed for listening. What I'm going to do now is hand over to Professor Sanyal, who's going to talk to us about the clinical data, Professor Sanyal. Thank you.

So we heard a lot about the basic mechanistic rationale for using pan-PPARs. We move on to now looking at the clinical trial data. And so my name is Arun Sanyal and as noted over here, I'm the co-PI for the NATiV3 trial.

Okay. So the foundation, the clinical foundation for where we are today started with this NATiV3 trial, which was a Phase IIb trial, which is a very classic Phase IIb trial. Remember, this trial started many years ago and the world has sort of evolved since then. But it was a straightforward 2 doses of lanifibranor versus placebo, biopsy at the beginning, biopsy at the end. But what was remarkable about this was, 2 or 3 things. One, that it was less than Stage 4. So excluded cirrhotics. So there were some people with Stage 1 disease.

Number two, it was 24 weeks study. So it was a relatively short study. And of course, we were looking at the 2 classic endpoints. One is resolution of MASH without improvement -- without worsening of fibrosis and the other one was improvement in fibrosis without worsening of MASH. So I'm going to show you the data over here, but also showing some of the comparable data from some of the other molecules that are currently under development.

And what I'll point out to you over here is not to necessarily obsess about any single number. But what it shows over here, these studies are of different sample sizes you will see. And they are also very importantly, of different durations. The inclusion criteria are not exactly the same. So I think obsessing about individual number is probably not the best way, but it gives you [indiscernible]. The goal of Phase IIb is to give you enough confidence to go into Phase III and to design your Phase III program for success.

So what you see over here, this was the first molecule that actually hit both endpoints, which was a combination of MASH resolution and fibrosis improvement. So there's [indiscernible] up there, and it was the first one with a 7% in placebo, 31% at the higher dose of lani, and the comparable numbers are shown for the other molecules that are over here.

Now if you break it down into the 2 individual components, what you see is that these are the data for fibrosis improvement. A lot of people obsess about fibrosis improvement because fibrosis tells you about proximity to cirrhosis. Cirrhosis is when you have clinical outcomes. So fibrosis improvement gives you greater confidence that you are actually going to slow down or reverse the progression towards cirrhosis. And here again, 24% versus 42%, almost a doubling compared to the placebo arm for lanifibranor comparable data are shown for some of the other molecules that are currently under investigation.

And when you look at MASH resolution, invariably for most drugs targeting the underlying root cause the MASH resolution numbers are a little bit higher than the fibrosis because you first have to basically put the fire out. That is the MASH, and then that translates into fibrosis improvement. So it follows sequentially. And in these short-term studies, remember, there's only 24 weeks, only 6 months, which at the time was thought really, how could you even show that?

Because at the time these studies were being designed, it was felt that it takes 2 to 5 years to see fibrosis to shift. And then, of course, there was this trial, the FLINT trial, other trials that showed that it could be moved relatively faster. So over here, we are seeing a very robust benefit, both in terms of MASH resolution and fibrosis improvement. So as -- while all this was going on, the world keeps moving, and our large population of patients with MASH continue to age.

And with the aging, we are seeing more patients with diabetes, and there's a global trend that within the MASH population, the proportion of people with diabetes keeps increasing, the proportion of people with more advanced fibrosis keeps increasing. This is sort of the aging of the cohort effect. So we've previously shown, these are data from the NASH CRN that [ Daniel Wang ] showed that even early on, within 2 to 3 years, you're beginning to see a little separation that diabetic patients tend to progress more than the nondiabetic patients.

And what you see on the other side, on your right-hand side, is that lanifibranor in Phase IIb nicely reduced A1c over and on top of any background therapies that the patients received. So again, this gives us a lot of reassurance that we're not only treating the liver disease, but all of the metabolic dysfunction around the liver that is also driving liver disease. And remember, these are competing threats to life. And in the long term, at least as physicians, we are very interested in making sure all the threats to life are taken care of.

So when you actually take -- look back then into the Phase IIb data, and look at all these end points in our diabetic population to really see are these people well served with this molecule. What you see again compared to -- so you have all the endpoints listed over here. So we'll go from top to bottom. So resolution of MASH and improvement in fibrosis. If you look at the 800 milligram, clearly, it works somewhere for these different end points between 3 and 7.5 to eightfold jump in the response rate and then a little incremental jump over to a 1,200-milligram dose.

So what it shows is whether you talk about resolution of MASH, resolution of MASH and improvement in fibrosis and then particularly in the lower 2 sets of data, where you look at the F2, F3 population, remember, this is our target population. Once you get to F2, your overall risk of mortality and your liver-related event starts going up, which is why from F2 onwards, we call it clinically significant fibrosis because that's when people start having outcomes. In those populations, you see these retained benefits.

So even in a higher-risk diabetic population with F2, F3s, you are seeing that the benefits are actually retained. To continue on this sort of conversation about the overarching benefits beyond these liver-related endpoints, what you see on the 4 quadrants, in each of these, you see actually improvement in liver enzymes, which is, of course, a classic way of looking at liver numbers. But you do see, I think, Will showed the improvement in HDL cholesterol and triglycerides.

It's relatively flat on the LDL and then an improvement in A1c and then markers of insulin resistance, both liver and whole body muscle. So sort of a really nice profile of metabolic benefit. And then in those days, we were very concerned and especially with a short study, whether histologic assessment, which carries some noise will -- might mislead us. So we want a reassurance that we want some biochemical markers linked to disease development and disease progression that would say, this is really -- we're looking at real data.

And so we had some fibrogenic markers. Pro-C3 is a marker of fibrogenesis as opposed to fibrosis alone. And then we have markers of apoptosis, which is CKT, some inflammatory markers and compared to placebo, as you can see, lanifibranor had a beneficial effect on these. Again, telling us that these histologic changes that we saw that this actually there's real biology behind it. This gives us reassurance. So of course, efficacy is one side of the story. The other side is tolerability always.

So when you look at this, you can see overall in the Phase IIb, there's really no signal that really dramatically jumped out. I will point out to you there were a couple of things, a little bit in a few patients with anemia, very easily manageable and nobody who actually had to really stop because of any of this. But otherwise, there was really no -- nothing that jumped out in terms of tolerability.

Most patients took the medicine and were able to handle it quite well. I will also point out that a small amount of weight gain that was noted is part of the PPAR gamma profile. And it ranged between 5 and 10 pounds, sort of the average for those, and it was a small number of patients, it was 10% of these patients. So that's actually -- the weight gain is the number of patients or percent of patients who experienced weight gain as opposed to amount of weight gain.

And then, of course, the question is, if they do gain some weight, is that a bad thing for these patients? So what we see over here is a lot of data over here. So I'll walk you through it a little slowly. So what we've done is in the lani arm broken it down by those who had stable weight, moderate weight gain, or those who had more than 5% weight gain. And then for the placebo arm, there are 2 -- it's a dark one, which is a stable weight and the light set of data, which is those who had weight gain. And what you are actually seeing over here, number one, is that regardless of weight gain, the HOMA-IR, which is a marker of insulin resistance, the triglyceride level, the ApoB, which is the cardiovascular ApoC these are cardiovascular risk factors.

There are liver enzymes. This is the liver fat with the FibroScan and the C-reactive protein, all moving in the right direction. So they're still being metabolically more healthy. They are less metabo inflamed than despite that weight gain. Now look at the placebo data on the other side over here, and you're seeing all the numbers going in the opposite direction. So a little bit of weight gain in the placebo arm had a much different biochemical and physiologic impact than in the lani arm. So this, again, points out that, yes, you do get some weight gain, but the patient is still getting a lot of metabolic benefit in this context.

So that has to be placed in context as we think about these drug therapies. So together, all of this provided the basis for the development of the NATiV3 or our Phase III program, which, as you heard, is now fully enrolled. We're now eagerly waiting to get it to the finish line. And so essentially, you have the main cohort, which has about 1,000 patients very -- we are recapitulating the same population, recapitulating the same design.

So we expect to recapitulate the results of what we saw in the Phase IIb study. And so you're seeing a noncirrhotic F2, F3 fibrosis, 72 weeks. And those who sort of screen failed many of these people and had F1 to F4, they're going into this exploratory open -- exploratory cohort with 400 patients who will also get randomized. So then at the end of 72 weeks, there is a possibility for the 48 weeks extension. Now the key readout is going to be at that 72-week mark. But then there is a 48-week extension where those who were previously on placebo will get put on, will get randomized to 800 or 1,200. And the rest who are on 800 or 1,200 will stay in their original dose frame.

The primary endpoint, histologic is this composite endpoint of MASH resolution and at least one-stage fibrosis improvement. And the key secondary endpoint, of course, are the usual ones of MASH resolution and fibrosis improvement.

Now those who are on GLP for more than 3 months on a stable dose and meet the eligibility criteria will be allowed in. And then, of course, this is all in the statistical power, with a large number of patients that we have to be able to clearly demonstrate the histological benefits of lanifibranor. The baseline demographics that can be shared as sort of you can see it's about 58% female. We are seeing the data for NATiV3 versus NATiV3 side by side, and you can see very comparable. So we're basically recapitulating our Phase IIb study population, very similar to many other Phase IIb, Phase III programs, nothing unusual.

Now we will have more F3s in NATiV3 simply because in the first one, we had 20% stage 1 patients, and now we don't have Stage 1 patients in the Phase III because that's not the target population. It's stage 2, stage 3. So we -- those get replaced by the more advanced. And you could argue that bridging fibrosis or stage 3 is really the sweet spot in MASH where you can still turn the ship around relatively easily and they are at clearly increased risk of outcomes for sure. And then this is their liver disease profile. This speaks to the increase in the F3 proportion that we expect to see. But you're seeing, again, very similar LSM, SCAP, FIB-4, AST, ALT, all the usual liver-related parameters.

So we're really recapitulating our Phase IIb program. Our co-medication profile, majority of our patients are not on an SGLT2. They're about 10%. And so far, pretty low numbers with SGLT2 and GLP-1 receptor agonist. We're getting about 10%, 14% in that -- about 14% were on GLP-1s previously. So if you take 1,000 patients, we should be -- we're very well positioned to be actually able to even see whether -- what the incremental gain over in this particular population would be. With the caveat, these are people who are on GLP-1 and still met eligibility criteria after a period of GLP-1. So it's not all GLP, but it's a select population on GLPs. So what I think I've shown you here is that the baseline characteristics for the NATiV3 and NATiV2 are quite comparable.

The design, of course, is virtually identical. There's a greater representation of patients with type 2 diabetes. And of course, we have more F3s. But there's a strong efficacy signal in diabetic patients in Phase IIb with fibrosis improvement and MASH resolution that were a little bit higher in type 2 than in non-diabetic patients and the numbers are provided over here.

These numbers are placebo corrected by the way. And then NATiV3, therefore, I think we're well positioned to, again, as I mentioned, to look at also the incremental gain over background GLP-1 kind of therapies. And I think we can say that with this differentiated pan-PPAR mechanism that Will very eloquently went to -- walked us through, I think this puts us in a very good place and we're looking forward to getting this trial in NATiV3 finished and hope to present those data in a year, 1.5 years' time. And so next, I think, now we've gone through the trial data, and I'll hand over to Dr. Nid Afdhal, who is going to walk us through sort of his real world experience. So we're taking you all the way from basic mechanisms through the trial data to what actually happens in the real world. Nid?

Thanks, Arun. So good afternoon, everybody. I'm Nid Afdhal, I'm a hepatologist, I have a long-standing interest in liver fibrosis across multiple diseases. And I am also a practicing clinician with a very large practice of patients with all sorts of liver diseases, including MASLD and MASH. We've heard from the last 2 speakers, very eloquently, the pathophysiological profile of how a pan-PPAR can work. Incredibly important because it's targeting all of the key components that lead to disease progression.

It's targeting inflammation, it's targeting apoptosis. It's targeting the fibrotic mechanism through the inflammatory and apoptotic pathways, and we've heard of the really outstanding results that we're seeing in the initial Phase II trial for a short duration of treatment. So our expectation, and it's just an expectation, clinical trials have to complete is that we're going to see a significant response in terms of the results of the NATiV study and that, that response will give us another therapeutic option. Why is that important?

As I go through what's happening in the real world, what you're going to see is that no new treatment comes out in a vacuum. It comes out and what is actually happening in practice. And where does that treatment fit in and what role can that treatment play and how can it be optimally utilized to benefit our patients. I hope I'm going to show you some of that because I think we're excited about treatments with new mechanisms of actions. So if we look at what we have had and we still have it today, and this is actually probably the slide that indicates what we spend most of our time talking to people about, which is lifestyle modification.

We want people to change their lifestyles. We want caloric reduction intake. We like some of the fancy diets that are out there like the Mediterranean diet, the low-carb diets and stuff. We want to promote weight loss, all right? Now this 5 years ago was done through conversations. Now it's done through modifications that take place with incretin use. So we get a lot more weight loss. We promote exercise, why? Because exercise improves insulin resistance. It affects the basic mechanism of disease.

It has muscle utilizing carbohydrates and it has muscle improving hepatic health. So these are still very, very strong there. And then we have the bugbear in the room, which is alcohol. And it's very important to realize that many, many of the patients who progress their disease are not heavy alcoholics but they drink alcohol, and they have a component of what we call MET ALD, which is metabolic alcoholic liver disease. The combination of the 2. And alcohol cessation becomes very important. It's a key factor when we think about some of the agents that we're using today because some of those agents actually take away both the cravings for alcohol and they also make patients less likely to drink as much as they were in the past.

And again, I'm thinking of the incretins in general. Weight loss works, but it's hard to get it, all right? It's hard to get -- prior to the GLP-1s and the incretin families, we really weren't seeing a lot of weight loss. But if you look at some of the older data and the older literature, which was biopsy controlled, what they showed was that weight loss is associated with lots and lots of the histological benefits that take place when you treat people and try to reverse MASH.

And you actually can end up with fibrosis regression when you have significant amounts of weight loss in the 10% range, but not everybody will have fibrosis regression. And overall, that's very, very important. You can look at it in other way, and you can look at it according to bariatric surgery. Now bariatric surgery, you promote significant weight loss. You also get metabolic changes that take place. But again, not everybody benefits from the weight loss.

It's somewhere around 40% will have reversal of fibrosis with the weight loss that comes from bariatric surgery. So weight loss per se is very important, but it's not enough, all right? It's not correcting all of the problems that we have to deal with. Now we have 2 drugs, all right? So we have choice. Choice is always very good. We can use a drug individually or we can use drugs in combination because a lot of treatment of complex diseases requires multiple drug use. So we've done all of the initial, be a good boy, don't drink alcohol, lose weight, do all these cool things. And most people haven't done it.

So now we're going to go to what we have available to us. And I've put this up as a way, and this is a personal opinion, as a way that we look at the 2 choices we have between the various families of incretins and Resmetirom. And as you know, both agents are pretty good at MASH resolution. Now these are placebo-adjusted numbers, which means this is the difference from the clinical trials of those on the drug versus those on placebo.

And you can see that MASH resolution is pretty good. Then we look at fibrosis improvement. You would have to say this is modest, all right? And this is fibrosis improvement from the Phase III trials of 72 weeks of treatment. Remember, the data that Arun showed you was better at only 24 weeks of treatment. And the longer you treat people, the more resolution it's possible to get from fibrosis. Fibrosis resolution takes that key word of time. So this is a modest improvement that we see in fibrosis across these drugs. They have certainly got other benefits.

They both have some degree of benefits on type 2 diabetes and cardiometabolic benefits, but that is where the GLP-1s really strike out strong. You're all well aware of this that there are significant improvements that take place in all of these parameters of cardiometabolic health. And again, we want to point out that we're treating a patient, a person and what most people with MASLD or MASH die from. They die from cardiometabolic disease, all right, that's what they die from that. They have heart attacks, they have cerebrovascular events, they get progressive renal failure. So you have to consider the improvement of cardiometabolic disease as a key factor of treating a patient. That's why we like what we see in the cardiometabolic profile of the pan-PPAR agonist like lanifibranor.

We see good cardiometabolic benefits across both diabetes and across cardiovascular risk factors. And then that comes the component of ease of use. And ease of use is a very, very important component when physicians make choices of what to use, all right? If you work like I do in a major liver center, in a major university and a big, big hospital, you have something that a lot of people don't have. And that's resources. You have really good resources. I have nurses, I have PharmDs. I have nurse practitioners, all of whom are being trained to be experts in liver and cardiometabolic health and they can help us with all of these issues that we face. Titration of GLP-1s, tolerability and dealing with the side effects, which is relatively straightforward, patient-related concerns and the high discontinuation rates that we hear about for GLP-1s don't happen as frequently as you think when patients are managed appropriately.

Our retention rate is about 85% at 1 year. That means that we keep patients on treatment, especially if you're seeing the cardiometabolic benefits. Having said that, Resmetirom is a phenomenally easy treatment to use. The side effects are relatively easy to deal with, the GI side effects, and very well tolerated by the majority of patients. So let's look at how we've been doing over the last year. This is a snapshot of some data on our patients from maybe a month ago. And this just looks at the patients that we have and what they are on. Now I'm putting this up because I want you to understand that the real world is different from the clinical trial world.

And it's different from the FDA-approved world, all right? It's the real world. It's when you're faced with the patient, you have to decide what to do. So let's start off by looking at who we're treating. So if you look at the disease stage, these drugs are approved for F2, F3 fibrosis. This data is only about patients who are started on treatment in the NASH and hepatology clinics. These are not diabetics like Arun mentioned, they come in already on an incretin. These are people that we have decided we want to treat because they have features to suggest cardiometabolic disease and liver disease.

And you can see that a significant proportion are F0 to F1, and a significant proportion are F4 or cirrhotic, all right? That's not what we should be treating. But it's a patient that we're treating and they have reasons for us to treat them. And F2, F3 account for about 1/3. When you contrast that with Resmetirom, much more focused utilization, predominantly in the F2, F3 population. And again, different practices go in different ways, but biopsy has disappeared from armamentarium in clinical practice to a great degree. And the majority of these patients are staged based on something like FibroScan elastography, which we use basically as our go-to test for staging.

Now what is approved recently for the treatment of NASH is obviously Wegovy? The reality is that we treat them with a whole variety of different GLP-1s. Why? The why is because we can't control what GLP-1 we can get for an individual patient. We have no ability. We can't say, well, we absolutely must have X because different payers have different preferential GLP-1s. And our decision is to treat the patient with a GLP-1 for the liver and cardiometabolic benefits. And so we will use whatever we can get. Therefore, you can see that there's a broad range of utilization of these drugs in our patient population.

More interestingly, is how is Resmetirom used. And a lot of the time, the patients that we see, about half of them already come in on a GLP-1 and they come in on the GLP-1 and they have evidence to suggest that they already have ongoing and continuing MASH. They have high FibroScan scores. We're worried about them. They have abnormal liver function tests. Many of them are not on the optimal dose of GLP-1, so we will up the dose of the GLP-1, but a lot of those patients go on combination therapy. And I think when you talk to people that are in big centers, you'll realize that about 40% to 50% of our patients that are on Resmetirom are on it on top of a GLP-1, all right, which is very important because that may look like what the future in the therapeutic space may be as we get to 2028, and these newer, more potent, we hope, drugs like lanifibranor get approved.

It's a process, all right? You have to go through a fairly, fairly big process to get this, you have to diagnose and stage the liver disease as it's appropriate. You need to have a lot of support to get them particularly for the GLP-1s. Again, there's differences in different areas of the country as to the ease of access to these drugs, Massachusetts, where I work is relatively good in terms of allowing us to prescribe these things. And we have been also recently, since their approval, being able to get with the specific diagnosis of MASH, we've been able to get GLP-1s approved for the treatment of MASH.

We've also got it approved for the treatment of sleep apnea, everybody with MASH has sleep apnea. So if we have difficulty getting it approved for diabetes or obesity we just say, it's for sleep apnea. Because at the end of the day, we always want to treat our patients. And then the question becomes, and this is an important question because nobody has answered this question yet, and this paradigm will change over time. More people will enter the treatment pathway for both of these drugs with MASH as the primary indication.

And what we haven't seen to date specifically is what is success? We haven't been asked by payers yet. What is the success of your drug? How do you know that it's working. So we need to develop, and there are some guidelines, although those guidelines are very nonspecific. We have to develop individually what we believe is evidence of good success. And when we put people on these drugs, what we're looking for is a stepwise improvement. We're looking for the first step on either of these drugs is improvement in steatosis. These drugs melt fat out of the liver. You can look at this based on the clinical trials and based on the MR data but it shows that they melt out fat.

You can lose 60% to 70% of hepatic fat fairly quickly. So our first step at 6 months is as the has the CAP score on the elastography gone down, is the fat improved? And then the second step at 12 months is how is the fibrosis doing. Is it stable? Has it gone up preferably, has it gone down? But so long as there's stability in that score, we're also very, very comfortable to say we're having success because, again, resolution of fibrosis takes time.

So the MASH world is a very, very interesting world because it's not just liver disease. It's cardiometabolic disease, where the liver is also one of the major player. We don't follow the guidelines simply because in reality, you're dealing with patients. And so a lot of the incretin use that's being used is expanded outside of some of the guidelines, they're there for MASH drugs alone. When you look at the diagnostics that are being used in the real world, it's all over the place.

And it's very unclear how people stage the liver disease to say it's F2 or F3. And those staging things that we use today are also not foolproof. So a lot of the decision analysis to treat somebody with MASH is based on clinical risk factor profile, ALT levels, FibroScan scores, et cetera, and you try to compile all those together and determine whether you're going to treat somebody. What that means is that you're undertreating some people and you're probably over-treating some people. But at the same rate with such a huge population, it really is a lot of people that are out there. You need a lot of resources to use incretins, but I think that at the end of the day, incretin use is something now with the new indication that we're going to see more and more of our liver and GI colleagues, but mostly our liver colleagues begin to use more and more of these.

And this, I imagine in 2028, a great proportion of the people that we see are going to be already on baseline treatment with an incretin for its other cardiometabolic, et cetera, things. Resmetirom use is simple, and it's being prescribed, and it's doing well in F2, F3 patients in terms of its utilization. You have to say that overall effectiveness, and effectiveness is basically how effective it is in clinical practice.

We don't know yet from real-world data, but both agents is relatively underwhelming. It hasn't hit the 20% mark rate in clinical trials. And in the real world, in the majority of cases, true clinical effectiveness is worse than the efficacy that you see in clinical trials. What that actually means is that you're going to see all these people on GLP-1s and 80% of them probably are not responding adequately in terms of their response from the liver point of view, although they may be responding well from the cardiometabolic risk factors.

So that secondary benefit of the cardiometabolic benefit, I think, is what's going to drive its use in patients with MASH. So where will we be in 2 years' time in 2028, 2.5 years' time. When we begin to see some of the newer, clearly more potent agents from Phase II coming out and available for use, we'll have a lot of patients. And as Arun pointed out very nicely, the number of patients actually just keeps going up and the number of patients with complications, including diabetes, keeps going up.

So we're going to need better antifibrotic agents. We're going to need agents that can push that envelope up, 25% is really, really good, 30% above placebo is outstanding in terms of what you would expect at this stage. And we're going to be seeing these drugs being used on top of majority of patients who are on GLP-1s. So the world of the opportunities in MASLD are going to be very different in 2028. We're going to have background therapeutics. We might have -- we'll probably have data on some of the early combination therapies, but we're going to have a space in which more potent, more effective agents that have both anti-fibrotic, anti-inflammatory, anti-apoptotic and cardiometabolic effects like lanifibranor are going to be really effective agents to add in and to treat patients with MASH and MASLD. Thank you for listening to my opinion, not fact.

So I'd like to ask the 3 physicians and Henry, whom we haven't met yet, but we will, why don't we come on up and populate the chair. So thank you. So Henry?

My name is Henry Chang. I'm the Executive Director at the Fatty Liver Foundation, which is a patient advocacy organization established in 2019 by Wayne Eskridge. I think some of you may know Wayne who's a MASH patient and I'm based here in New York city, really delighted to represent a patient perspective in this discussion.

Thanks, Henry. I want to thank the physicians, Dr. Sanyal, Afdhal and Alazawi for, I mean, look, your passion is clear for the field and for the work, and we're grateful for your time here today. I'm going to open with a briefing yet and get into a quick -- an important Q&A here with the panel. But when I first met Wayne Eskridge, back when he was starting the Fatty Liver Foundation, his story was very clear. He was basically living a life in Idaho, I think, retired and happy, He just moved out there with his wife Rosemary. And he went in for a routine laparoscopic gallbladder procedure and they popped in the camera and what they found was nodular cirrhosis due to NASH.

Now that story in 2015 would make us think, "Wow, that's terrible, right?" No one knows anything about this disease. That can't happen anymore now, it's 2025, right? So prior to coming to Inventiva a few months ago, I was at a small startup in Boston, and I had a colleague there, whose husband, middle 50s, healthy, energetic, young children, went in for a routine procedure, and it's 2024 and he walked in and he was determined to have cirrhosis due to NASH, completely asymptomatic and completely undiagnosed. So when Nid was mentioning that he lives in a world in which people come in and they sort of have all these cardiometabolic problems, and they're not being adequately diagnosed, and we look at the world today, and you heard all of the physicians say, we have more work to do.

I just wanted to ground it in a real story that we have more work to do. And that whatever Wayne Eskridge did back in the late 2010s to kind of get the Fatty Liver Foundation up and going, we're not done yet. So with that, I'd like to open for the first question.

I want to go back to Dr. Sanyal. What I want to note, Dr. Sanyal talked about numbers, right, looking at the graphs and you said sort of don't get bent out of shape or wound up around a given number. But on the other hand, Nid had just talked about that. He called some of the data that he was looking at modest, [ his decision ]. And then he put out this sort of 20% threshold. And then we also know, as all of you have said that this is about outcomes in the end. Liver-related and cardiovascular outcomes will ultimately drive this field. So the open question starting with you, Arun is, how are we supposed to think about all of this?

Yes, I think this is a really important point. When we think about looking at these numbers and outcomes, first thing to keep in mind is this is context specific. If you have a disease that would kill you 100% within the next 6 weeks, if you had a 1% improvement, I think you would try and take that right? So it's really context specific. But here, we are talking about a disease, which is a chronic disease, runs its course over 20 years or so, and there may be some people who are rapid progressors, but that's another conversation.

But really the -- over here to assess benefit in the long term compared to -- and the natural history itself, waxes and wanes and there are -- it's a very heterogeneous disorder. And so I think I agree with Nid that about a 20% placebo-corrected benefit is -- gives you reassurance that things are -- this is enough to say, yes, we have something that works because there's also noise around each of these numbers because different studies have different results.

So there are confidence bands around the natural course of the disease and the trajectory of the disease. And until we have a number of these studies that have completed their outcomes, gone all the way to outcomes and read out the results, we will not be able to actually say what this means in terms of real hard outcomes, which is ultimately where the rubber meets the road.

But the surrogate endpoints that we use, whether it's histology, whether it is NITs, these are road stops along the way. And we're making a best guess over here along the way based on these. Although it is fact, it's not an entirely a guess, so it is based on all of these NITs, other markers, have data to support that, yes, when you see these changes, it's likely that these will translate into clinical benefit.

William, I'd like to go to you on this point. I want to sort of stay in the depth here. So Paul and [indiscernible] paper was, what, 11 years ago now that said it's all about fibrosis. But when you open with your talk, you spent a fair bit of time talking about the cardiometabolic elements here, particularly the role of insulin resistance and the role of the adiponectin, the adipose tissue itself in driving the disease. How do we reconcile this? You've got fibrosis on the one hand, which everybody agrees is important. We just have 2 physicians up there, who said 20% looks like it's a reasonable benchmark. But you spent a lot of time talking about the metabolic drivers. So how do we balance that?

Yes. Thank you. I mean I think to keep it really simple, if you've got 2 cars driving down the motorway or freeway, then the one that's going to get to its destination first is the one that has traveled the furthest, not the one that is revving its engine the loudest. But the engine had to get it there in the first space. And so if you don't think about what's happening in terms of where the drive is coming from. Then you're not going to be able -- Professor Sanyal said, turn out the fire, and that's really what you need to be able to do.

So I think, yes, absolutely. We don't want liver disease to progress. We measure that progression based on fibrosis. We know that you've got more fibrosis, you're more likely to run into trouble sooner. That doesn't take away from the fact that actually what you really want to be seeing is an ending of the disease process itself. And if I want to use another analogy, then think about viral hepatitis actually the treatment for hepatitis C. The thing that's really made that difference. The reason why the transplantation rates are as they are now in terms of they've plummeted, is not because medicines to treat viral hepatitis reverse fibrosis. It's because they take away the primary injury. And I think that's what we need to understand.

So what does -- it raises and Nid and Henry coming to you both, Henry, I want to start with you. This is complicated, right? So how do patients understand any of these dynamics? And if they do, what matters to them. And if they don't, what do we need to do to make that better?

Absolutely. One thing I wanted to mention is that the Fatty Liver Foundation, we've been running an annual national survey. It's called the The State of Steatotic Fatty Liver Care in America. We'll be presenting some data at the Liver Meeting. And this is a survey based on the sample size, about 1,000 diagnosed adults in the U.S. And what's clear is that people really -- what really values for the patient is whether treatment affects their day-to-day lives, whether that treatment reduces fatigue, reduces hospitalization rate, improves cardio metabolic health. That's what really matters to the patient at the end of the day. So when we talk about oral therapy that has a potential to shut down those drivers of disease activity that Dr. Sanyal mentioned. That's what really resonates with the patients and the providers.

So great answer. And Nid I saw you nod your head when Henry mentioned that, you obviously spent a lot of time talking in the real world, right, not the FDA world, not clinical trial world, What were you thinking when you were nodding your head?

So I think Henry is totally right. Your patients come in with symptoms sometimes. So those symptoms are often fatigue, there are often sleep disturbances. Their anxiety related to having this diagnosis and anxiety related to their cardiometabolic disease, their diabetes and obesity. And the reality is, is that every time you show them an improvement in something, you reinforce to them dramatically what benefits they're getting.

Whether that improvement is normalization of their ALT, whether it's reduction in their CAP score, showing their steatosis and their liver is improving. And whether as my friend, Dr. Younossi has done in Washington, you show quality of life improvements as Henry said, in daily functioning. These things all stress why patients want to be treated. And quite honestly, most of those benefits, a lot of those lifestyle benefits are coming from utilization of the incretin class of family. Fibrosis is something that they worry about, but it's less important to an individual patient than the daily factors of living.

It's important to us. And then I would make the comment that there is no liver disease, none at all, in which you are -- where you can stop the mechanism of injury like a drug like lanifibranor does with stopping inflammation, stopping apoptosis, improving all of the lipid parameters. There is no liver disease, in which fibrosis cannot be reversed. So long as it's not fully established irreversible cirrhosis. Every liver disease that we treat, we can reverse fibrosis in and the biggest driver of the reversal of fibrosis is control the disease and give it enough time. That's it. It's true for every single one.

William, I saw you nodding your head, too, and I want to stay here for a moment because when Nid gave his talk, he said that many of the GLP-1 patients sort of come in needing additional therapy, the point that despite the fact that they're on GLP-1, you just said again. But I'm sticking with the real world here, both you and Arun talked a lot about both the extra and the intrahepatic sort of targets that are needed to address the disease. Can we lean into that a little bit more, right? How does that look in the real world? What is it that we need to address exactly? And it's less about lanifibranor and more about the diversity of the mechanism that we may need to come to bear on the problem.

So we have 3 patients who come to clinic. Over the next 5 years, one might have a cardiovascular outcome, which might be the terminal event. Another one may have a liver outcome. So somebody may have a stroke. So I think it's really -- and I think Nid touched on it a little bit that this is a very interesting disease in the sense that it takes us, liver doctors away from what we know, which is very focused on the liver, to back to internal medicine because now we also have to look at these competing risks to life.

And so the person who has bad NASH, also has got likelihood of having diabetes, heart disease, vascular disease, risk of non-hepatic cancers, all of the above. And so we have to make this assessment to help the patient, we need to address the totality of the threats to the patient. Some of these we may say the primary care physicians, you take care of it. But then increasingly, as we understand this common biology that connects a lot of these conditions, and we are becoming the caretakers for these patients because frequently, what happens in a real world is that as soon as a patient is identified to have liver disease, their primary care physician gets a little nervous about managing all of their different drugs because of the liver disease.

And so essentially, we become their "doctor." Managing literally all aspects of their care. And so in that setting, it is really important that we not only address the liver disease, but also these other comorbidities that are threats to live by attacking the core route problem, which is linked to insulin resistance and the state of what we call metabo inflammation.

William, you're nodding there? What please go ahead.

It's obviously very dangerous to nod.

I know.

Because you get picked up.

Because I paid attention to it. yes.

No. So I totally agree. I totally agree. One of the privileges I have in my role is I look after the diabetes, the obesity departments as well. And I'm learning from my colleagues that this is not new in that we have got different drugs that could do different things. And for the right patient makes the selection that addresses the unmet needs in that individual there in front of you. So our cardiologists are very comfortable choosing the best beta blocker in combination with the best antihypertensive choosing the right lipid-lowering medication. We simply need to recognize that, that can happen in a hepatology clinic just as well as it can happen in a cardiology clinic.

So to your original point about intra versus extrahepatic. Ultimately, I don't think the patient in front of me necessarily is too concerned what the MOA is, what silo we decide to put the medicine in. Does it work? Does it achieve what it needs to achieve? Is it a tolerable pill burden? Is it something that the side effect profile is compatible with everything else that's going on because that's the reality in which we prescribe. And I think that's what, Nid, you described really elegantly is actually even down to the fact that you'll use whichever incretin you're allowed to use that we individualize to the patient in front of us.

So having something in the back pocket, in the armamentarium that starts to address the underlying insulin resistance. And I still think most people would agree, mechanistically, that is the main driver for progressive liver disease.

Henry, does that match with what patients want. I mean the sort of diversity of options? Or do they want their doctors to come in and say, "Look, I have this new magic drug. It could be a GLP-1, it could be any other drug that's going to be approved. Do they just want the doctor tell them take they should be fine, how do patients think about this?

I think most patients really don't pay too much attention on the mechanism of action, as William mentioned. Every patient really wants to know can they stay on this treatment, right? So ultimately, we talked about oral once-daily treatment that doesn't trigger significant GI issues and injection fatigue, especially for those patients who can't tolerate GLP-1. This is where convenience is often underestimated in valuation modeling. And patient ultimately are seeking for simplicity and tolerability. And that's what's really serve as the bridge between commercial success -- and clinical success and commercial success.

So Nid, we've come back down right again to the real world, right? So we were talking earlier some of the folks up there and myself, but Nid was not there. As an anesthesiologist, you learn one lesson early on. If the drug doesn't go on the body, nobody goes to sleep. It's very straightforward. But really what Henry is just saying is that patients just want a drug if I'm interpreting it right, that they can take and that they know they can keep taking it because if they don't, things don't work out.

So Nid, coming back to you here, right, in the real world, how important will that be you sort of said at the end of your talk in the world of 2028, looking forward 2 years, how important will that kind of adherence challenge be to the field.

So it's always going to be a challenge based on the 2 things, the ease of use, so injectables are more complicated than oral agents, obviously. Even though the injectables are not that difficult, and once a week is not that onerous, especially since many patients are diabetic and taking lots of medicines.

And then obviously, the side effect profile is the other one and their management of whatever side effect profile is out there. I mean it's very difficult for me to have an issue with a lot of the treatments that we use because I know that we have a lot of support in our system that helps the patient get through it. And I grew up in the world of high-dose daily interferon therapy. And if you grew up in that world, you know what side effects are. And you know how difficult it is to keep people on treatment.

And so I find that will an oral GLP-1 come out? Hopefully. And if it does, that may be a really good thing in combination with other agents that are more liver targeted. Will we get combination GLP-1s with other mechanistic drugs in one shot? What are we thinking of? We are thinking of may be a GLP-1 plus an FGF21 as a one-shot therapeutic. Will that come out in the next 3 to 5 years? Maybe. But at the end of the day, no matter what you do, you're totally right. You have to treat the person. And if you -- if that person can't take a GLP-1, it's useless. It's completely useless. So you have to think of something else. And that's the reality of where we live.

So this will be the final question. I want to give each of the panels an opportunity to respond, but I'm just generalizing the same question, though. Nid, you talked -- you just said, this is where I think the world might look like in 2028. I want to go back to something, Andrew, new CEO said at the very beginning of this.

He said, "How interesting, right, that this market, how it's developed so quickly. Just 4 years ago, we've nearly -- we've 50% or more growth in the awareness of actual diagnosed patients, but the base was pretty big. I think we showed 18 million people to something around 400,000. So now back to the group, evolving landscape, William, it was in your deck, that beautiful slide, metabolic landscape evolving. Now to each of you, maybe just starting with William, where will we be in 2028 do you think?

Well, it depends which health care system you're talking about and that's half joking, but half real in the sense that, that depends on how these medicines land and how systems allow us to use them. But where will we be? I think we will have a better understanding of how a general metabolic health service looks like. I think physicians will be more acknowledging of the need to be holistic. So you'll -- that sort of liver on legs that you were describing will be a thing of the past.

So I think physicians will be better positioned because there will be medicines that are licensed for the treatment as there are now coming in my territory, then I think that will drive recognition because it's not okay to ignore somebody's ALT, their FibroScan score, if there's actually a medicine that could be used for that. So I think physician practice will change to recognize those more. And I think we will be starting to get real-world evidence exactly as you present today that -- those sorts of early nuggets of information are super important, and they will craft our thinking around this. And the more things we've got in the cupboard that we can use, the more rich our offering to our patients will be.

Arun?

So I think it's always a little dangerous to predict -- try and predict the future.

Lucky for you this is only a webcast...

Yes. So I think the way I'm thinking about this is a few -- there are a couple of thoughts to build on what -- I agree with everything Will just said. So I think the future is going to be more holistic, more integrated. Already, we're seeing in the larger medical centers the move towards these metabolic health programs, bringing cardiology, liver, everybody together, so you're going to see more integration. Number two, my sense is that the GLP because of the widespread benefits around so many different facets of metabolic ill health is going to be part of the background and the future is going to be additional organ-based therapies layered on top of that.

And it may be that in that kind of setting, a combination of an oral GLP plus something else, whether it's lani or something else, could be a base on which other things could be layered on. These are all open with question marks around them, with more organ focused therapies for those who have more severe and/or individual end organ disease. And then I think at the end, again, the more choices there are, I think we're going to move towards prevention and also instead of waiting for organs to become terribly sick and then try and get small incremental gains at great cost, move towards prevention. And that sort of is the way I see this whole metabolic health space evolving.

But the more -- there will be a bigger portfolio of options. So given the heterogeneity of the disease, there are trade-offs. As Nid said, there's no free ride. Some people may have to deal with nausea and say, I can handle this, but I will take this. This is my -- I'm willing to take this poison and some people will say, 'I may gain a little weight, but I'm getting the same benefits and I don't want to feel nauseous and I'll take the other option.' So I think having more options is great for patients and great for physicians in order to be able to take care of our day-to-day business.

Henry, you're going to get the last word from the panel. It's not a shock, right, that the doctors have this all planned out, of course and it's straightforward. You think the patients will be along for this journey too.

I'm completely in line with what Arun just said. I think the future, certainly, it's very bright. We're looking at the expansion of the armamentarium in the fight against MASH. What we see in the last couple of years that there's more awareness around the need to detect this condition early. And there's certainly a number of industry-sponsored disease state awareness campaign that's making meaningful impacts, getting more and more people paying attention to this condition, getting their health care providers engage. So we hope -- we're quite hopeful that the percentage that's been shown earlier that 10% being diagnosed can only continue to expand with the expansion of available treatment that in the coming years.

Well, I want to thank the panelists for the genuinely good dialogue, I enjoyed it. I'm sorry for watching you all nod, but it was great for me. I think we're going to finish with the panel, and I have a wrap-up for Andy.

Good. Well, thank you, everyone. The -- I think it's -- bring it over. So what we're going to do is we're going to bring up everyone for a Q&A. But before I do that, I wanted to just summarize what we heard today. Number one, treatments have been approved, but unmet medical need persists for liver-directed therapies. I think we've heard that loud and clear. Two, lanifibranor, oral liver-targeted drug candidate that addresses both intrahepatic liver and extrahepatic metabolic cardiovascular components of MASH within 6 months. So I think this is one of the key differentiators for lanifibranor, it's also there's a direct anti-fibrotic effects, but also acting on the entire body.

Our trial is fully recruited Phase III, and that trial design has been informed by a positive readout of a IIb study. And we're now focused and structured on being able to execute delivery of the top line data and as soon as the second half of 2026. So with that, I'd like to invite up the panel. Mark, come on up and Jason, and then we're just going to take Q&A and Martine.

Without microphones.

Yes. Yes, without microphones and the physicians as well.

[Operator Instructions] Let's start with Seamus and then go to Yasmeen.

Seamus Fernandez from Guggenheim Securities. So just a couple of questions. Maybe we'll start with the panelists first. The availability of Rezdiffra versus the opportunity for lanifibranor, I think we had Dr. Afdhal kind of provide some thoughts early on. But I wanted to get a sense of the development of the market as you see it with the availability of Rezdiffra, how has the endocrinologists actually started to integrate with the hepatologists. And how much has the availability of that product changed the sort of ability to catalyze forward movement? And how much more room do you think there is to go?

Yes, go ahead.

Yes. Nid and Arun, I think.

So I'll take the last part of the question first. There's lots of room for growth and improvement. The reason being -- there's still a lot of nonresponders both to Rezdiffra and to Wegovy, I was the PI for the ESSENCE trial as well. So clearly, it's better than doing nothing. But there's a lot more room to grow. So if I again pull on the hepatitis C analogies, this is somewhere like the Peginterferon days as of -- we're not in the daily interferon, we have moved to Peginterferon. I mean, I'm dating myself. For those of you who remember those days, we're midway in this journey. And so I think there is lots of room.

Endocrinologists are slowly coming around. They're lagging behind a little bit for a variety of reasons, and I can only hypothesize why that might be so. But I think Rezdiffra was developed in the liver space. So I think it's largely lack of awareness, lack of familiarity. And of course, because it's a thyroid pathway, they might have their own biases about how thyroid functions work. But the whole Rezdiffra development came from the liver community. So obviously, the liver community has embraced it with both arms. And we are -- all of us are, I think, using it on an everyday basis. And in general, experience is good, but there's lots of room for growth.

I'm going to start off with saying where will we be in 2028, I'm going to be on a beach having a very nice long drink because I should be retired by then. But where this space will be is it will evolve out of the hands of hepatology alone, out of the hands of gastroenterology and into the hands of many, many other specialties that are involved in cardiometabolic disease. I said this was going to happen with hepatitis C, nobody believed me and it absolutely happened.

It will happen with this disease state as well. And the reason it will is that there are so many patients that need to be treated. And that treatment as it becomes more simplistic, which I believe it will, with the introduction of some of the more novel and oral therapies is going to be taken out by people interested in cardiometabolic health.

Right now, Rezdiffra is the go-to drug for gastroenterologists. Why? It is because it's much easier to give, and they have a lot of patients they followed for years with NASH. So they've got an oral agent, it's easy to use, and they want to use it.

They've got these patients that haven't treated it in the past. That paradigm is going to change as awareness goes up as other specialties get involved. So I see this as like Arun said, we're going to have cardiometabolic units that deal with the whole patient and all the different aspects. So I'm very excited if endocrinology gets involved. I'm very excited if internal medicine and fatty practice get involved, which I think they will eventually.

And just one follow-up question. As you think about the importance of bone health in these patients as they progress. And we have some questions that have been raised around other potential targets in the space. How much does that matter in your evaluation of the patient, obviously, targeting the liver. But in terms of introducing a new therapy to F2, F3, how much might that weigh into your decision process? So if again, FGF21, we saw some interesting, maybe not the best impact on potential impact on bone. So questions there. I'm just wondering how you think about sequencing therapy given some of those impacts?

So we need to see more of the actual data on bone health to start off with. We basically got a snapshot of a negative effect on osteopenia at a fairly high rate and a fairly big decline over a short period of time. We really need to know more about the patients who they were and where they go. Bones and liver disease go hand in hand, right? So bones are important to people who have advanced liver disease. Osteopenia from liver disease is incredibly common, acceleration of that can lead to very bad outcomes.

All of us have PBC patients that have died post fractures post really simple things that happened from their osteopenia. So it needs -- we need more clarity and we need more knowledge. And it is a negative side effect that we need to understand a little bit better. I just don't think we know enough about it.

Yes. I'll just add to that, that it's only in the elderly patients, the average middle-aged patient or a young patient, it really doesn't configure that much into our clinical decision-making. But in the older patient where there's this whole concept of frailty, increased risk of fractures, they have bone density studies done as part of their medical assessment, it has nothing to do with their liver disease anyways. And in those, I think we work with the primary care physicians to try and maintain bone health as best as possible. That's standard of care.

We're used to it, too, by the way. I mean, don't think that for us, it's nothing big. I mean look at what happened with Tenofovir and the 2 different forms and all the bone health stuff in HBV. So we're used to it. But we need -- I don't think we've got enough information yet on it.

Yasmeen.

Thank you for the great presentation, my God, what an awesome panel, right, a decade of work in MASH and 2 approved therapies. Two questions.

2.5 decades.

Yes. That's right. Two questions and then a very easy question for Mark. I think maybe we'll go with the easy question at the end. One question is that I think it was very clear is that fibrosis gets better over time, NATiV2 was a 24-week time point, NATiV3 is 72 weeks. Given the depth of data that we have had over many years, how do we think about deepening of a fibrosis response on the lanifibranor arm? And also, how does that change in the placebo arm. So if you could talk about that? And then the second question is, it was very nice to correlate weight gain with improvement in metabolic parameters, which I think a lot of investors are missing. And we also know that the weight gain occurs within the first 6 months and then plateaus. Maybe it would be good to understand the biological rationale for the plateauing effect. And then I'll ask Mark my easy one at the end.

Maybe start with William for the first part of that, can I put you on.

Yes. So -- sorry, I was thinking about the second part. So the first part of your question. No, no, that's fine. The first question was?

How does fibrosis should change from...

So the answer is we don't actually know. But I think what would make logical sense is that if you have improved insulin sensitivity, if you've activated tissues to keep burning out the fat from the liver, one would anticipate that if you saw a signal, you wouldn't then see a reversal, number one, because that's happened with other agents that have fallen by the wayside. Next thing to say is that not progressing is really important for the patient. I said it earlier, you don't need your liver to look amazing. You need not to get to advanced fibrosis and cancer risk. And then over time, yes, indeed. I think that we would want to start to see improvements and see the fibrosis get better. We also know that the earlier the fibrosis is the more likely it is to melt away, Nid told us that. So if we're not treating too far down the line, then I think we should be seeing those improvements, but we need to see.

I'd would like to add to that. I think what we learned from the efruxifermin story is that yes, you saw a certain degree of improvement at week 36 or 32, whatever that first time point was. But then when we went to week 96, there is a remarkable jump. So there are clearly people who are late fibrosis responders, if I may use that word, as opposed to the early fibrosis responders. And I don't think we have a lot of data yet to understand the biology. I can hypothesize that there are people who have NASH resolution at Week 24 or 36 who have not yet shown fibrosis improvement. That's the population that if you keep that MASH cooled off, the fibrosis benefit will catch up, which is why you got to treat the root cause. It comes back to again what we were talking again and again, about creating the root cause in the underlying disease to improve the fibrosis.

Liver biopsy sucks, all right. In simple terms, it is a test that has so much variability in it across all liver diseases. And so there's an error there. You asked a question that prevention of progression, what's going to happen to placebo, 96 weeks is and certainly 72 weeks, it's long enough to see a significant proportion of placebo patients worsen. So there should be more worsening than that was present at the 24 weeks.

Data is always presented on the primary endpoint predominantly, which is reversal. But in fact, progression is equally, if not more important. The FDA in Phase III studies doesn't like you to present who progressed to cirrhosis. Why? Because they want to use that as an endpoint for the long-term outcomes. Bad, that's really bad because there's a proportion of those F3s on placebo that progress. And we're not giving that data.

So that's a bad thing. The most important thing to look at, which actually Arun pointed out so beautifully is that all the biomarkers, which are far more active than liver biopsy are telling you what's happening in a patient with lanifibranor in the Phase II, all the biomarkers, every single one moved in the right direction. And when you see that, you know that the activity is there to prevent disease progression. And so I always look -- everybody looks at the number at the endpoint. I always look at the biomarkers because they're actually telling me what is dynamic and the liver is a dynamic organ. It's always in the phase of having fibrogenesis and fibrosis regression.

So you want to speculate, if at 24 weeks, you see 18% fibrosis improvement, you could see significantly more clinically significantly more at that stage at 72 weeks, sorry.

All right. And we had a question about the mechanism of weight gain, William, maybe back to you on that one or do. Actually, maybe we'll go to our Medical Director here, Jason.

Sure. So if you were to ask any general practitioner, what happens to a diabetic when you get them better controlled on insulin, the answer would be they gain weight. So answer number one, the weight gain is a pharmacodynamic marker of lanifibranor's efficacy period, full stop. As insulin sensitization improves, glycemic handling improves, the best controlled diabetics are often the most ones with weight problems. You know the inverse of that from just living in the world today in America, the Atkins diet is all about depriving your body of insulin and you lose weight under those circumstances. So step one, insulin sensitization drives weight gain. Step 2 is, as Arun mentioned very clearly, he asked the right question in the talk, what does this mean for the efficacy of a therapeutic. It depends on the therapeutic. If you live in a world and you gain weight, we showed very clearly with our placebo data, you're going to have worse disease.

On the other hand, GLPs clearly showed weight loss matter. But as we've also know, it's not enough. What we find with lanifibranor is that it's the one thing that cuts cleanly through both problems. If you gain weight on lanifibranor, your efficacy is not only in evidence, it's actually better than patients who don't gain weight. So it's an unusual circumstance in which we find ourselves today, where we all acknowledge that weight matters in NASH/MASH. On the other hand, in the case of lanifibranor, it is the 1 exception to that rule or maybe said differently, weight does matter, but not in the way that we've generally been simplifying it. Is that fair? Anything more to add?

Yes. Just to add 1 thing because, yes, as you mentioned, the apparent plateau effect with lanifibranor that was a Phase IIb study. In contrast to PPAR gamma drug like pioglitazone, right? If you remember the PIVENS study, you saw a linear weight gain right through the 2-year study phase, the hypothesis there. This is a pan-PPAR agonist, right? So it's probably PPAR delta, we think, that's contributing to that. It's important also to remember, as Jason just mentioned, this is a healthy weight gain.

And as we've seen in combination with SGLT2 inhibitors, and also with pio in combination with GLP-1s, can be likely completely aggregated in combination on top of the GLP-1.

Ritu Baral, TD Cowen. Actually, one of my questions is a follow-up to that. In the many investor conversations we've had about that weight issue, I wanted to ask the doctors where is that inflection point for you guys as far as that weight gain. When in your mind, do you say up until this, obviously, it's a function, it's an on-target effect of this mechanism. But beyond it, now we're a little worried like where is that line in the sand? And then I have a follow-up on secondary end points.

Yes. So why don't we go to the physicians first and then we're going to go to our patient advocates as well.

So because we know it's relatively so-called good weight gain, you can set your mind a number where you're saying if the patient gets a 3-kilogram weight gain, I can live with that. But the real question is what can the patient live with, all right? And that's the real question. And that requires education. That requires a discussion about, look, there may be a 2- to 3-kilogram weight gain. And that's okay because that's good weight. And we will look at that in context to the other parameters that show that the medication is working. And that's a key conversation, right? I mean if somebody gained 5, 6 kilograms, I would be worried. I would be like this is probably going to give them a lot of problem. They actually don't like the edema as much as they don't like the weight gain. When you talk to the patients, they don't like the edema. Nobody likes fat ankles.

Yes, I think it's very individual patient-specific, some patients will handle it quite well, and some are less tolerant of the weight gain. But somewhere in the 5 lb. to 10 lb. is something that most patients can live with depending on, of course, where you start. For the lean patient with NASH, it could be a different conversation. But again, you have to be careful that if you see a lot of excess weight gain then is there something else going on in the issues about edema, heart failure. This is a population at high risk for all of the above. We see it in our placebo arms in every study as well. So I think it requires clinical evaluation, but 5% to 10% is sort of in general range?

Henry, do you want to comment on that?

Yes, just building on what Arun mentioned, it's very patient specific. There are individual patients among our membership who are more interested in weight loss. But the primary driver for why patients get on treatment, the fear of dying from cardiovascular disease. So if you can show them while on treatment, that you cardiometabolic and liver metabolic are all moving in the right direction. That's what really -- how most patients define treatment success.

So my second question actually...

Ritu, can I add 1 sentence to that. So that is the 3 Cs that patients we talk about. One is cardiovascular, one is cirrhosis, one is cancer. The fibrosis-stage all of this they are not interested, they don't get it. But they get cirrhosis, but I don't drink. Am I going to die? So cirrhosis, everybody gets, nobody wants either of the 3 Cs. So it's really about that at the end of the day.

So to that point, what has folded into NATiV3 to compete with that evidence of metabolic benefit and those markers along the same parameters that we had this discussion about GLP-1s. They help this, and they help that. They help insulin sensitivity across tissues. What is the NATiV3 trial going to generate to help start that part of the discussion because one of the important parts of our model for lanifibranor is this idea of patients come in, they're on low-dose GLP. And then you have something like lani. So do you add lani? Or do you try to try to titrate up and deal with those potential side effect issues like what's actually easier even from an endo. So what is that -- what are the secondary end points that address that cardiovascular, maybe cancer is too long, but that part of the reach for GLP-1 first argument.

I can start, but I'll then pass it on to Jason to really provide a lot of detail. I think from a high level, you have to remember the time frame over the -- over which these outcomes occur. And so within the 72-week time frame, unless you have 8,000, 10,000 patients, you'll probably not see a cardiovascular outcome signal. So you look at surrogates like improvement in lipid profile, markers of vascular inflammation, CRP, those kind of things.

These are standard classical portfolio of markers that are linked to cardiovascular risk. And that, for sure, would all be included. From that you sort of draw the lines to connect the dots, if you will, to sort of impute a metabolic health benefit. In the long term, hopefully, there will be larger data sets that will actually show real numbers for metabolic health outcome benefit. But I'll pass this on to Jason to provide more details about specifics.

Yes. I think the detail is actually Arun gave a perfect framework. And it's very simple, call it, XYZ access, x-axis, did drug work that you hit the primary and the key secondary endpoints. Axis number two, when you look at are there noninvasive technology data to support those histologic endpoints, just like we showed in NATiV2. There could be FibroScan, other Pro-C3, diversity of those to give confidence that the drug works.

X and Y all about does the drug work, Z are those cardiometabolic components. Are they tracking in the right direction? And then you take those data sets and you just cut them in quartiles or thirds, is it the same in people that have no weight change, modest weight gain and more extreme weight gain. We believe that those that core XYZ cut in that way will give providers enough data to have the conversation that the physicians just said, but I would go back to the physicians. The question is, is that right? We think it is based on the Phase IIb data. That's why we built the study that way. That's all it providers would need. But I believe that we're aligned on that, but it's a good come to Jesus Jess because we're all here talking about it now.

Could NATiV3 generate the sort of data that would let you in your head comp adding lani versus titrating up the GLP. It will?

I actually think it will because you'll have patients coming out of that you'll see better control of all the various -- you'll see improvements in hemoglobin A1c. So most of the people that we see that are already on low doses of the incretin, so therefore, diabetes-related issues. We'll see improvements in the factors that were mentioned in terms of CRP lipid profile, fasting glucose. They're measuring everything. So I think that there will be enough to say, "Oh, look at this, these are all positive cardiometabolic events." I don't need to take the risk of titrating that patient's GLP-1 up to full dose and risking him having bad side effects or whatever.

I can just add on top for both the cardiometabolic benefit and the liver benefit. I can consider just straightforwardly adding lani to the current dose of GLP-1, you don't have to titrate it up.

I can add 2 more points to that. And one is that at an individual patient in the real world, you always have to do this balance between side effects, tolerability and benefit. And so you may get to a certain point, and we do this all the time when we're using Rezdiffra. Patient says, "Doc, I can -- I'm managing with 0.5 or 1 milligram of semaglutide, I don't want to be more nauseous." And they say, Well, you've been on it for a year, and your liver steatosis is still 16 or 15, so then we add Rezdiffra. So I think something like this will happen.

Remember, the second point is 14% of NATiV3 has GLP-1 in the background. So we will be able to show also whether -- what the benefit level is in that subpopulation is and whether it's comparable to those who were GLP naive coming into the study and whether there's incremental gain. And in parallel track, ESSENCE is still ongoing. And the ESSENCE trial by '28, '29, at some point, in that general around '29, we will have sort of 5-year outcomes data as well. So you'll be able to get at full dose semaglutide, what the profile looks like, people getting diabetic dose GLP-1 and then add lani, what does that look like? And then we'll have a lot of options based on tolerability and this whole conversation about how do I maximize benefit while maintaining tolerability at an individual patient level.

Edward Nash from Canaccord. I wanted to ask about compensated cirrhotics. So if you are F4 and you let's say, if you look at Dr. Afdhal's slide, you start with the FGF21, would you now consider -- because I know we hear a lot about everyone is now used to the needle, we'll just wait longer. It's not a problem, we'll keep them on the therapy even if they move back, say becoming F3. But do you see yourselves now moving away from the FGF21 after the patient is kind of pulled away from being compensated cirrhotic to, say, bridging and then moving to something like lanifibranor, would that be the next likely option given the cardiometabolic effect.

And then just a second question while I have you, is also we hear a lot about, obviously, combining with GLP-1 for obvious reasons. But are there any other mechanisms out there that seem to make a lot of sense. We see the FAS inhibitors are now going to be combined with Resmetirom to look at in clinical development. Is there anything that you see that lanifibranor would be appealing potentially mechanistically to combine with?

Two good questions. We're going to answer them. I'm going to challenge my panelists to be relatively summarized in the responses, just so we can move to more questions as well.

So I just want to open on the cirrhotic question and then turn it over to the docs. We have to be clear on just one thing, given the forum we're in. right now, the what's on the table for lanifibranor, which is the same on the table for the modular therapeutic. This is an approval in F2, F3 noncirrhotic NASH. I think what the world holds for the future of cirrhotic NASH is sort of being informed real time.

The comment from Inventiva's perspective is that cirrhosis is more than an anatomic description of an F4. There's a physiologic component to cirrhosis, which is really critical to understand. And we'll have -- we at Inventiva will have more to say about how we're thinking about that next year. But for today, everything we're talking about is our view of lanifibranor as an F2, F3 treatment option. We want to make sure that we're clear on that. We're not at all talking about F4, but that being said, the doctors can talk about anything they would like.

William is about to say something.

No. I mean I was going to actually echo that to say that there isn't anything licensed at the moment. But what I would say is that -- again, if we draw from other liver disease areas, I don't think anyone would be bold enough to think that once the patient has gone from having circles on their biopsy if they have one to having just shy of a circle on their biopsy means that there is a major change in how you need to follow them, how you need to treat them, how intensive you need to be. So I think that actually, what I would advocate for is treatment at F2, F3 to prevent progression to cirrhosis because that's the real opportunity cost because that's the point at which you could then say, over to your family physician to continue that medicine.

So I think that's where I'd like to direct that. In terms of your specific question, could you imagine pulling a drug and then adding in another, that could well be the case. That could well be the case. But I think we need to see what the data look like. And we also need to understand the protoplasm. What is the patient actually like? So far, we've been talking about people living with MASH. Actually, there are many, many peoples living with different MASHs, and I think as we do more on the basic science side, we start to understand that better as well. So I think this is a real sort of work in evolution. But I think that once a patient is cirrhotic, I think, their risks will be they'll stay with them for a while, certainly.

Yes. The only additional thing I would say is that there's a lot of opportunity for innovation in this area, with respect to fibrosis regression induction and fibrosis regression maintenance.

Thanks Annabel Samimy at Stifel. So we've heard now several times that you want to get to the root of the problem, and it seems that lani truly is getting to the root of the metabolic problem with MASH. So outside of the F2, F3 sweet spot that you're all talking about. Given that you are getting at the source of disease, how do you plan on leveraging the F1 and F4 data that you might be collecting from NATiV? And could this give you possibly broader opportunity?

I'm going to pass that question to Jason.

Thank you, Andrew. Good question. So F1, I think the physician said earlier on the panel that we're going -- it's a prediction, but the prediction would be that we're moving into preventative posture in the future and less treatment oriented, still very treatment oriented but more preventative. F1s really have a role there to play. Many years ago in Intercept, Intercept had approached FDA, there was an exploratory cohort in the Phase III pivotal trial at that time, it was larger than I think the NATiV2 clinical trial, it was like 287 patients, if I remember right. That was the largest cohort of F1 data that had ever been assembled. FDA in that era was not interested. I don't think that's the case anymore. I think they're much more interested in understanding more about that F1, so we're interested as well. On cirrhosis, my only point here is just echoing what Arun had said, we have an exploratory cohort in NATiV3.

We have about 75 to 100 patients approximately that will likely be cirrhotic that we'll have an opportunity to look at and it's our view that these cardiometabolic drivers matter to outcome because if you look at NASH, if you're fortunate -- maybe I'll say it this way, if you're fortunate enough to survive a cardiovascular event, then you'll ultimately die of a liver-related event with NASH cirrhosis. So you have to pay attention to both. This idea that you construct a trial that filters out for cardiovascular events. So you have this pure look at the liver-related events. It looks good on paper, but Nid said earlier, that's not the real world, that's the world of a clinical trial or FDA. In the real world, the patients that come in our office with NASH cirrhosis will have a much higher risk of cardiovascular death first before they get to the liver, we're very interested in that. Martine?

Yes. What I just wanted to say is that the pivotal trial, NATiV3, as you know, is constructed with a primary endpoint and a population that is described in the protocol, right? So we are targeting F3, F4. But yes, in the exploratory cohort, we have the other 2 groups. And payer rules, right? FDA, it's not the right -- the world of real-world data, but we have to present data in what we put in the protocol, right, which is the targeted population, but of course. I mean we will also describe the patients in the exploratory cohort and make the link, but the statistical analysis plan that is validated by an agency before you submit and you all know that have to target the population that you enroll and the primary endpoint that you measure, right?

And then the world is evolving and some colleagues here discussed their experience in the past, but we see over the last couple of years now, FDA being more open to look at what's happening more holistically. If we can say, in the patients that are not exactly the same patients like the one that you have in your targeted population, the population from the protocol. So I'm very encouraged actually, yes.

Just 1 final point on that. Important to remember though, in that exploratory cohort of F1 and 4s, we're not looking at histology. They're not being repeat biopsy. We will, of course, have safety in NITs and all of that. It's part of the broader data set. And then also important to remember in the real world, as has been said [indiscernible] approving, patients identified who are appropriate for therapy are not biopsied typically, right? So they're selected based on NITs.

So it will be good to have the reassurance of the additional safety and efficacy -- noninvasive efficacy data across the broader spectrum of disease.

Okay. And if I can maybe ask a slightly more granular question maybe a little bit more loaded for the physicians. So obviously, this MASH market is extremely heterogeneous. How do you think the market is going to be segmented. If you've got 80% of the population that have Type 2 diabetes that seems like it would be perfect for lani. So maybe you can see where FGF21s fit in for a very severe patient who might be tipping into cirrhosis. But where would leave Resmetirom that doesn't have that's, yes, liver targeted, but it doesn't have that much efficacy and it doesn't have any impact on the metabolic markers or some of the other markers that you deem very important. So just your view about that.

I would not take such a pessimistic view of Resmetirom. So yes, I think all our patients are either prediabetic or they are diabetic because they're all insulin resistant. So there's a good rationale for a drug like a GLP or lani or anything affecting metabolic insulin resistance. Having said that, I think, there are clearly people who are fibrosis nonresponders to all of these individual drugs. So there's going to be lots of room when people don't respond to one, they can be put on another. There may be other patients who may not tolerate one drug versus another.

And then you have to switch drugs around, it's not that different than in hypertension when you start with lisinopril and then you get the little dry hacking cough. And then you have to switch to something else and then you go to losartan and then your creatinine goes up, and then you go to switch to something else. You go to a calcium channel blocker and your feet swell up, and then you keep bouncing around. I'm just telling my own story over here.

So I think having multiple shots at goal is good for the patients and Resmetirom clearly does work. Their actual real-world data that was presented at EASL looked really, really good as well. So I would not discount drugs like that. I think FGF21s probably will have a much bigger role for those who already have very advanced fibrosis. And because in terms of fibrosis benefit, they're really -- especially the data in the cirrhotic population, I think, looks very, very exciting.

I wonder if -- Nid, do you agree?

Resmetirom has a place. It's not going anywhere, it's a very solid drug and it does have some metabolic benefits. And so I don't see an issue. I think what will happen is it's too difficult to say that we're going to segment the population based on certain parameters or certain patient clinical characteristics. That's really, really complex. And in the disease that's so common, it's extremely, extremely difficult, all right? So I think that what we're going to do is we're going to use some very common and easy, definable clinical parameters to determine what's best on an individualized basis.

And I think that the good clinical trials will help us understand what is best for the individual patient as they analyze their data. And I think the good clinical trials, and I hope Arun's trial is a good clinical trial, will enable us to actually determine what is success, all right? So to me, the biggest issue is not worrying about how many choices I have. It's worrying about making the right choice for the right patient and knowing that I'm actually succeeding in what my goals are for that patient. That's if we can get that out of any clinical trial, it's a winner.

Ananda Ghosh from H.C. Wainwright. Just wanted to tell that it was a fantastic set of panelists and learned a lot. One of the questions I had was that when we look at the lani story over the past like 2, 3 hours, there are a couple of things which kind of stood out, insulin sensitization, glycemic control, fibrosis improvement, the weight gain, which is metabolically active. Now having this set of profile and assuming that the NATiV3 does replicate several aspects of these observations. How do you think that lani should position itself given the learnings from Rezdiffra or Wegovy's approach to educate the physicians and payers with respect to the market.

Actually, I'm looking at our physicians for that. Where do you think it fits into care?

So I think it's a really -- I think it's a very interesting position, isn't it? Where do you -- the question is where do you start? Because your patient doesn't start afresh. So that choice is not really up to you to make that call because the patient walks into your room with all of that back story there. So they may already be on a GLP-1. They may already have seen somebody who's decided to put them on various other medications. They may have tried certain things, they may have come to you differently.

So I think where to position it is an understanding of the disease process. So what we need to be doing as physicians, we need to make sure that we're well educated enough. We need to make sure that we've got the environment right for the patients and that we need to understand what the different mechanisms of action are.

Now in a sort of a blank territory like the U.K., we're preparing for that as specialist societies, and we're interacting with our primary care colleagues, our endocrine colleagues getting ready, watching what's happening here in the U.S., very carefully and then borrowing the learnings. But I think the key there is to understand what's happening in your patient, what their drug history is and then understanding this is where the role is. And yes, you're right, you've enumerated all the different reasons why 1 would consider this medicine. And as colleagues have said, all the other medicines have got their things to consider as well. But you've got to fix it for the patient in front of you.

So your question was semi, where should they position this? And that's not a physician choice as to where a company positions a drug. But if you look at it from the point of view of view who is going to be excited specifically by this mechanism of action where it goes. Look at our endocrinologists, educate them on NASH, even more, and they're pretty well educated, educate them even more on NASH. They're using 6 million patients on pioglitazone. They know PPAR, they like PPARs, and they're going to get a pan-PPAR with a better profile of activity and they're going to have lots and lots of patients with NASH. And they know the cardiometabolic status of these patients very well. I think they are a population that I would be very excited to see from my own point of view, getting involved in NASH. Look, at the end of the day, when we're all talking about all this, him and me and William as well are real card-carrying hepatologists. We deal with transplant, bleeding, liver failure, all of this stuff, okay?

So what do we really want? I want nothing but cirrhosis in my clinic. I love cirrhosis, all right? I like dealing with it. I like taking care of patients with it. And quite honestly, if every F2, F3 patient with MASH was taken care of by my endocrine or primary care colleagues and they looked at them from a holistic point of view, I'm a happy man. I'll just take my million cirrhotics and deal with that.

Sorry, just to add to that. I mean, let's remember that Novo and now Madrigal will be out there educating the endos to care about these patients more and more. And that's great for us, right? So assuming we get any launched in the early '28 time frame, we'll have the stage set for what is, I think, truly differentiated about this profile. And let's remember that the type 2 diabetic with advanced fibrosis due to MASH, as the physicians mentioned earlier, is the toughest to treat most at-risk patient, right? Starting with the fact that GLP-1s, I mean, a lot of these patients will be on GLP-1. So you know that they're resistant to weight loss, which is what indirectly leads to benefit on the liver side. So really adding lani to a patient like that, I think, is the sweet spot. Of course, the drug is more broadly efficacious based on the Phase IIb data. But that's, I think, where the benefit risk, the value prop for this drug is strongest.

Got it. Very quickly, a follow-up question on the similar lines, is that as lani comes out in 2028, and given the biopsy noise and the shift in the fiber scan in the real-world practice, how do you see lani kind of utilizes this non-invest tools shaping adoption and reimbursement?

I mean I can't imagine that you're going to have medicine-specific criteria for treatment at a macro level in a disease that is looked after by so many different people. I think our understanding of what the noninvasives mean is growing. Our confidence with what success, Nid, you mentioned that, what that looks like is growing. And I think we, as a field, we'll understand that if you meet a certain threshold of eligibility to treat, then I think we'll end up treating. So I don't think as physicians, I don't want to see, well, you need a FibroScan score of X in order to have this medicine, but it's X.3, you're going to have that medicine, the payers might use that as a tab for on and off, but we would be advocating strongly against that.

And so really, I think it's about finding those individuals who need to be treated. And just as a follow-on to Nid, what we really want is for all those cirrhotics not to become cirrhotic. We'd love to trim down our practices and consider that everybody who turns up with that cirrhosis or decompensation or cancer was actually a failure of prevention in the first place. I mean that's the real goal.

So there are specific companies that have created barriers to the utilization of drugs without a doubt in the liver space. And the 1 you think about most was when the true DAAs came out for a viral hepatitis C. The payers insisted on a FibroScan score 15 or above. And we had patients that we clearly knew were very advanced fibrosis and cirrhosis who I used to send off to eat the cheeseburger and then I would scan them. And they would always have a FibroScan score of greater than 15, because a cheeseburger increases your liver stiffness quite significantly. I actually ended up being investigated by the State of California. So these are things that I care for patients, and you've got to do what's right.

I want to -- we're probably close to closing here, but I want to go back to the key question that we asked on Inventiva. What we heard at Inventiva from the panelists today are that the field needs 4 things at the time of lanifibranor coming to market. They need a drug that's patient-friendly and offers simplicity. They need a drug that addresses the metabolic drivers of the disease around insulin resistance, glycemic control. They need a drug that gets a fibrosis because that is still the #1 marker and predictor of long-term survivability. But if you ignore the underlying drivers of the liver disorder, the inflammation, hepatocellular injury, that fibrosis benefit will be short-lived. We think that the way that the NATiV3 study is designed and the data we've delivered on NATiV, if we hit on those, we have a vote, and we have an opportunity to play in that market. That's how we're approaching it.

One more question, I think. And then -- 2 more questions, I think we'll wrap it up. We're a little bit over.

I'll keep it short. I promise. Rami Katkhuda, LifeSci Capital. Maybe a question for you, Jason. I guess you mentioned 14% of patients came in with a concomitant GLP-1 use. Given that it's a 72-week study, how are those patients handled if they come off kind of GLP-1 during the course of NATiV3?

So for any concomitant medication in the trial or new starts, they're all protocol specified. I don't know that we're prepared today to get into that level of detail, but a patient that begins on a treatment option, call it, in this case, GLP-1 that stops that GLP-1. They're appropriately flagged and they're managed in our analysis plan. Our statistical analysis plan in a way that allows us to sort of impute what their data would have been so that in that case, we would be sort of penalized, you can think about it because we would have lost some efficacy. That will all be specified in our statistical analysis plan. Anything more to add there.

Great. Thank you. Ed Arce, WestPark Capital. Thanks for squeezing me in. I just want to add my thanks for putting this panel together, well timed about a year before readout. I have a couple -- well, actually, I'll just keep with 1 question given the time. And this is for the KOLs on the panel, kind of putting you on the spot here. I'm just thinking about as you look across the landscape, really, you've got 2 drugs that target F2, F3 are oral and our liver-directed and that's Rezdiffra and lani. And so kind of just focusing on those 2, how do you see -- what do you see as the strongest product differentiation on lani? In particular, as you think about perhaps switching from Rezdiffra to lani upon approval.

Any volunteers?

I think the word switching is a very, very early word. I don't think that you're going to switch anybody because you think 1 drug is necessary. At this point when we don't know what the response rate is to Lani that we're going to be thinking about switching. I think what you're going to be doing is looking at people who are failing to respond that may already be on the GLP and Rezdiffra and putting them on lani. I think what we've heard today from everybody, starting off with the mechanism of action and stuff, is that most of us as physicians like the metabolic profile and the cardiometabolic benefits of lani significantly. So perhaps in new patients, lani might be a first choice in comparison to what we're seeing with Rezdiffra. But Rezdiffra has 3 more years to generate more data, which it will do. And I have an incredibly open mind as to what the space is going to look like in 2028. And I think until I know what that space looks like, I'm going to leave myself very open to what I have as a choice to use.

Yes, I'd like to add, so the way I look at it is that when the -- I agree that on probably patients doing well, I'm not switching anything. But if they are a nonresponder, this gives me another option. One thing that I would also think about is the different lipid profile changes on Rezdiffra versus lani. Lani drops the triglyceride. Lani improves HDL, but Rezdiffra drops LDL cholesterol. So for specific patients, who have very high, say, you have a coronary calcium score of 80 and have a strong family history. And on high-dose statin, your LDL is still 105 million, I may use a drug to push there, which will give me still the liver benefit, but at the same time, reduce LDL without having to put them on a PCSK9.

So there are nuances to that. But other than that, I fully agree with everything Nid just said.

I mean I don't think we should think of this disease area as that wonderfully different to other cardiometabolic disease areas. I think the analogy has been used by all of us of hypertension. And I think that's a very good way of looking at this, different drugs, different classes, different efficacies across different receptors. All acceptable. And all that does is it allows us to have a smorgasbord. It's not the case that every time a new antihypertensive comes out, we all about face and change our patients. So that's, for me, not a bad analogy and probably not a bad framework for the evolution of the treatment landscape.

So I think that brings us to the end of our time. Thank you, everyone, for attending today and [indiscernible] over a little bit. And I want to thank our panelists as well in our physicians and patient advocate for being here as well. So thank you.

Thanks, everyone.